ULURU 10-K31 Mar 142013 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Jun. 28, 2013	Mar. 31, 2014	Mar. 31, 2014
	Dec. 31, 2013	Jun. 28, 2013	Common Stock [Member]	Series A Preferred Stock [Member]
Entity Information [Line Items]	'	'	'	'
Entity Registrant Name	'ULURU INC.	'	'	'
Entity Central Index Key	'0001168220	'	'	'
Current Fiscal Year End Date	'--12-31	'	'	'
Entity Well-known Seasoned Issuer	'No	'	'	'
Entity Voluntary Filers	'No	'	'	'
Entity Current Reporting Status	'Yes	'	'	'
Entity Filer Category	'Smaller Reporting Company	'	'	'
Entity Public Float	'	$6,377,738	'	'
Entity Common Stock, Shares Outstanding	'	'	23,588,110	0
Document Fiscal Year Focus	'2013	'	'	'
Document Fiscal Period Focus	'FY	'	'	'
Document Type	'10-K	'	'	'
Amendment Flag	'false	'	'	'
Document Period End Date	31-Dec-13	'	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets	'	'
Cash and cash equivalents	$5,119	$21,549
Accounts receivable, net	185,078	111,898
Notes receivable and accrued interest, current portion	777,710	260,444
Inventory	395,605	527,643
Prepaid expenses and deferred charges	123,812	194,448
Total Current Assets	1,487,324	1,115,982
Property, Equipment and Leasehold Improvements, net	638,614	845,535
Other Assets	'	'
Intangible assets, net	3,670,837	4,145,985
Notes receivable and accrued interest, net of current portion	0	1,041,776
Investment in unconsolidated subsidiary	0	0
Deferred financing costs, net	86,770	160,770
Deposits	18,069	18,069
Total Other Assets	3,775,676	5,366,600
TOTAL ASSETS	5,901,614	7,328,117
Current Liabilities	'	'
Accounts payable	1,734,725	2,340,782
Accrued liabilities	315,963	372,965
Accrued interest	13,360	41,141
Convertible notes payable, net of unamortized debt discount, current portion	1,147,057	1,089,619
Deferred revenue, current portion	58,959	45,227
Total Current Liabilities	3,270,064	3,889,734
Long Term Liabilities	'	'
Convertible notes payable, net of unamortized debt discount and current portion	0	751,543
Deferred revenue, net of current portion	898,133	835,553
Total Long Term Liabilities	898,133	1,587,096
TOTAL LIABILITIES	4,168,197	5,476,830
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' EQUITY	'	'
Preferred Stock - $0.001 par value; 20,000 shares authorized; Series A Preferred Stock, 1,000 shares designated; nil and 65 shares issued and outstanding, aggregate liquidation value of nil and $701,843, at December 31, 2013 and December 31, 2012, respectively	0	0
Common Stock - $ 0.001 par value; 200,000,000 shares authorized; 18,871,420 and 10,074,448 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively	18,872	10,075
Additional paid-in capital	53,336,127	51,336,931
Promissory notes receivable and accrued interest for common stock issuance	0	-985,287
Accumulated (deficit)	-51,621,582	-48,510,432
TOTAL STOCKHOLDERS' EQUITY	1,733,417	1,851,287
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$5,901,614	$7,328,117

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
STOCKHOLDERS' EQUITY	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	20,000	20,000
Common Stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, shares authorized (in shares)	200,000,000	200,000,000
Common Stock, shares issued (in shares)	18,871,420	10,074,448
Common Stock, shares outstanding (in shares)	18,871,420	10,074,448
Series A Preferred Stock [Member]	'	'
STOCKHOLDERS' EQUITY	'	'
Shares designated to Series A (in shares)	1,000	1,000
Preferred stock, shares issued (in shares)	0	65
Preferred stock, shares outstanding (in shares)	0	65
Preferred stock, aggregate liquidation value	$0	$701,843

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	Dec. 31, 2013	Dec. 31, 2012
Revenues	'	'
License fees	$48,688	$40,563
Royalty income	30,016	49,918
Product sales, net	291,864	280,113
Total Revenues	370,568	370,594
Costs and Expenses	'	'
Cost of goods sold	222,122	243,538
Research and development	788,242	832,931
Selling, general and administrative	1,288,050	1,791,221
Amortization of intangible assets	475,148	476,450
Depreciation	244,704	291,274
Total Costs and Expenses	3,018,266	3,635,414
Operating (loss)	-2,647,698	-3,264,820
Other Income (Expense)	'	'
Interest and miscellaneous income	69,686	61,719
Interest expense	-506,529	-328,248
Equity in earnings (loss) of unconsolidated subsidiary	0	0
Gain on sale of equipment	3,627	0
(Loss) Before Income Taxes	-3,080,914	-3,531,349
Income taxes	0	0
Net (loss)	-3,080,914	-3,531,349
Less preferred stock dividends	-30,236	-47,456
Net (loss) allocable to common stockholders	($3,111,150)	($3,578,805)
Basic and diluted net (loss) per common share (in dollars per share)	($0.21)	($0.42)
Weighted average number of common shares outstanding (in shares)	14,772,578	8,493,703

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Promissory Note Receivable and Accrued Interest [Member]	Accumulated (Deficit) [Member]	Total
Balance at Dec. 31, 2011	$0	$7,269	$49,750,792	($725,045)	($44,931,627)	$4,101,389
Balance (in shares) at Dec. 31, 2011	25	7,269,063	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Issuance of common stock in a private placement (in shares)	0	491,636	'	'	'	'
Issuance of common stock in a private placement	0	492	245,326	-245,818	0	0
Issuance of common stock for principle and interest due on convertible note (in shares)	0	1,987,992	'	'	'	'
Issuance of common stock for principle and interest due on convertible note	0	1,988	331,344	0	0	333,332
Issuance of common stock for services and wages (in shares)	0	325,000	'	'	'	'
Issuance of common stock for services and wages	0	325	129,675	0	0	130,000
Issuance of common stock - vesting of restricted stock (in shares)	0	699	'	'	'	'
Issuance of common stock - vesting of restricted stock	0	1	-1	0	0	0
Issuance of Series A preferred stock in a private placement, net of fund raising costs (in shares)	40	0	'	'	'	'
Issuance of Series A preferred stock in a private placement, net of fund raising costs	0	0	275,761	0	0	275,761
Issuance of warrants for services	0	0	48,776	0	0	48,776
Issuance of warrants in connection with convertible promissory note	0	0	457,912	0	0	457,912
Offering costs in connection with convertible promissory note	0	0	-42,710	0	0	-42,710
Offering costs adjustment - Series A preferred stock sale in 2011	0	0	31,961	0	0	31,961
Repurchase of common stock (fractional shares from reverse stock split) (in shares)	0	58	'	'	'	'
Repurchase of common stock (fractional shares from reverse stock split)	0	0	21	0	0	21
Accrued interest on promissory notes for issuance of common stock	0	0	14,424	-14,424	0	0
Accrued dividends on Series A preferred stock	0	0	47,456	0	-47,456	0
Share-based compensation of employees	0	0	17,915	0	0	17,915
Share-based compensation of non-employees	0	0	28,279	0	0	28,279
Net (loss)	0	0	0	0	-3,531,349	-3,531,349
Balance at Dec. 31, 2012	0	10,075	51,336,931	-985,287	-48,510,432	1,851,287
Balance (in shares) at Dec. 31, 2012	65	10,074,448	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Issuance of common stock and warrants in a private placement, net of offering costs of $4,379 (in shares)	0	3,750,000	'	'	'	'
Issuance of common stock and warrants in a private placement, net of offering costs of $4,379	0	3,750	1,491,871	0	0	1,495,621
Issuance of common stock and warrants in a private placement, net of offering costs of $2,175 (in shares)	0	825,000	'	'	'	'
Issuance of common stock and warrants in a private placement, net of offering costs of $2,175	0	825	327,000	0	0	327,825
Issuance of common stock for principle and interest due on convertible note (in shares)	0	3,072,648	'	'	'	725,274
Issuance of common stock for principle and interest due on convertible note	0	3,073	915,257	0	0	918,330
Issuance of common stock for services and wages (in shares)	0	423,750	'	'	'	'
Issuance of common stock for services and wages	0	424	177,826	0	0	178,250
Issuance of common stock - 725,274 shares for cashless exercise of warrants to purchase 1,571,428 shares (in shares)	0	725,274	'	'	'	725,274
Issuance of common stock - 725,274 shares for cashless exercise of warrants to purchase 1,571,428 shares	0	725	-725	0	0	0
Issuance of common stock - vesting of restricted stock (in shares)	0	300	'	'	'	'
Issuance of common stock - vesting of restricted stock	0	0	0	0	0	0
Redemption of Series A preferred stock (in shares)	-65	0	'	'	'	'
Redemption of Series A preferred stock	0	0	-992,430	994,294	0	1,864
Offering costs adjustment - Series A preferred stock sale in 2011	0	0	8,000	0	0	8,000
Cancellation of warrants issued for services	0	0	-48,776	0	0	-48,776
Accrued interest on promissory notes for issuance of common stock	0	0	9,007	-9,007	0	0
Accrued dividends on Series A preferred stock	0	0	30,236	0	-30,236	0
Share-based compensation of employees	0	0	15,648	0	0	15,648
Share-based compensation of non-employees	0	0	66,282	0	0	66,282
Net (loss)	0	0	0	0	-3,080,914	-3,080,914
Balance at Dec. 31, 2013	$0	$18,872	$53,336,127	$0	($51,621,582)	$1,733,417
Balance (in shares) at Dec. 31, 2013	0	18,871,420	'	'	'	'

CONSOLIDATED_STATEMENTS_OF_STO1

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
	Dec. 31, 2013	Series A Preferred Stock [Member]
Issuance of stock in a private placement, net of fund raising costs of $14,514	'	$14,514
Issuance of common stock and warrants in a private placement, net of offering costs of $4,379	4,379	'
Issuance of common stock and warrants in a private placement, net of offering costs of $2,175	$2,175	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Dec. 31, 2013	Dec. 31, 2012
OPERATING ACTIVITIES :	'	'
Net (loss)	($3,080,914)	($3,531,349)
Adjustments to reconcile net (loss) to net cash used in operating activities:	'	'
Amortization of intangible assets	475,148	476,450
Depreciation	244,704	291,274
Share-based compensation for stock and options issued to employees	15,648	17,915
Share-based compensation for options issued to non-employees	66,282	28,279
Equity in earnings (loss) of unconsolidated subsidiary	0	0
Amortization of debt discount on convertible notes	178,548	97,901
Amortization of deferred financing costs	74,000	39,230
Warrants issued (cancelled) for services	-48,776	48,776
Common stock issued for services	158,250	130,000
Common stock issued for wages	20,000	0
Common stock issued for interest due on convertible note	127,343	89,622
Gain on sale of equipment	-3,627	0
Change in operating assets and liabilities:	'	'
Accounts receivable	-73,180	-66,477
Other receivable	0	26,410
Inventory	132,038	271,841
Prepaid expenses and deferred charges	70,636	17,074
Notes receivable and accrued interest	524,510	197,780
Accounts payable	-606,057	700,571
Accrued liabilities	-57,002	-3,577
Accrued interest	-27,781	28,088
Deferred revenue	76,312	184,437
Total	1,346,996	2,575,594
Net Cash Used in Operating Activities	-1,733,918	-955,755
INVESTING ACTIVITIES :	'	'
Purchase of property and equipment	-39,093	-64,349
Proceeds from sale of equipment	4,937	0
Proceeds from sale of intangible asset	0	220,000
Net Cash Provided by (Used in) Investing Activities	-34,156	155,651
FINANCING ACTIVITIES :	'	'
Proceeds from sale of common stock and warrants, net	1,823,446	0
Proceeds from sale of preferred stock, net	0	275,761
Proceeds from redemption of preferred stock, net	1,864	0
Proceeds from issuance of convertible note and warrants, net	0	467,290
Repayment of principle due on convertible note	-81,666	0
Offering cost adjustment - preferred stock sale in 2011	8,000	31,961
Cash paid in lieu of fractional shares	0	21
Net Cash Provided by Financing Activities	1,751,644	775,033
Net Decrease in Cash	-16,430	-25,071
Cash, beginning of period	21,549	46,620
Cash, end of period	5,119	21,549
SUPPLEMENTAL CASH FLOW DISCLOSURE:	'	'
Cash paid for interest	35,467	5,532
Non-cash investing and financing activities:	'	'
Issuance of common stock for promissory note	0	245,818
Issuance of common stock for principle due on convertible note	790,987	243,710
Issuance of 725,274 shares of common stock pursuant to cashless exercise of warrants to purchase 1,571,428 shares of common stock	0	0
Redemption of 65 shares of Series A preferred stock by offset of notes receivable ($969,000) and accrued interest thereon	0	0
Issuance of notes receivable in connection with June 2012 Note (see Note 6.)	0	1,500,000
Deferred financing costs in connection with June 2012 Note	$0	$200,000

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012
Non-cash investing and financing activities:	'		'
Shares issued on exercise of warrants (in shares)	725,274		'
Warrants exercised (in shares)	1,571,428	[1]	0
Preferred shares redeemed by offset of promissory note receivable (in shares)	-65		'
Promissory note offset on preferred share redemption	($969,000)		'

[1]	As part of the June 2012 Note, Inter-Mountain received a total of seven warrants to purchase, if they all vest, an aggregate of 3,142,857 shares of common stock, which number of shares could increase based upon the terms and conditions of the warrants. The warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017. Warrants for 785,714, 392,857, 392,857, and 392,857 shares of common stock vested on June 27, 2012, December 31, 2012, February 26, 2013, and July 15, 2013, respectively, and three warrants for 1,571,428 shares of common stock have been exercised. For the purposes of this Table, only such net vested shares of common stock from the fourth warrant (392,857 shares) have been included, based upon an exercise price of $0.35 per share of common stock. On January 22, 2014, we elected to offset and deduct the three remaining Investor Notes from the principle amount due to Inter-Mountain under the June 2012 Note and as a result of the offset and deduction the three remaining warrants terminated.

COMPANY_OVERVIEW_AND_BASIS_OF_

COMPANY OVERVIEW AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2013
COMPANY OVERVIEW AND BASIS OF PRESENTATION [Abstract]	'
COMPANY OVERVIEW AND BASIS OF PRESENTATION	'
	NOTE 1.	COMPANY OVERVIEW AND BASIS OF PRESENTATION

	Company Overview

	ULURU Inc. (hereinafter “we”, “our”, “us”, “ULURU”, or the “Company”) is a Nevada corporation. We are a diversified specialty pharmaceutical company committed to developing and commercializing a broad range of innovative wound care and mucoadhesive film products based on our patented Nanoflex® and OraDisc^TMtechnologies, with the goal of improving outcomes for patients, health care professionals, and health care payers.

	Basis of Presentation

	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) and include the accounts of ULURU Inc., a Nevada corporation, and its wholly-owned subsidiary, Uluru Delaware Inc., a Delaware corporation. Both companies have a December 31 fiscal year end.

	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ from those estimates and assumptions. These differences are usually minor and are included in our consolidated financial statements as soon as they are known. Our estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from those estimates.

	All intercompany transactions and balances have been eliminated in consolidation.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

	The following is a summary of significant accounting policies used in the preparation of these consolidated financial statements:

	Cash and Cash Equivalents

	Cash and cash equivalents include highly liquid investments with original maturities of three months or less. The carrying value of these cash equivalents approximates fair value.

	We invest cash in excess of immediate requirements in money market accounts, certificates of deposit, corporate commercial paper with high quality ratings, and U.S. government securities taking into consideration the need for liquidity and capital preservation. These investments are not held for trading or other speculative purposes.

	Accounts Receivable and Allowance for Doubtful Accounts

	Accounts receivable are recorded at the invoiced amount and do not bear interest. We estimate the collectability of our accounts receivable. In order to assess the collectability of these receivables, we monitor the current creditworthiness of each customer and analyze the balances aged beyond the customer's credit terms. Theses evaluations may indicate a situation in which a certain customer cannot meet its financial obligations due to deterioration of its financial viability, credit ratings or bankruptcy. The allowance requirements are based on current facts and are reevaluated and adjusted as additional information is received. Accounts receivable are subject to an allowance for collection when it is probable that the balance will not be collected. As of December 31, 2013 and 2012, the allowance for doubtful accounts was $907 and $18,932, respectively. For the years ended December 31, 2013 and 2012, the accounts written off as uncollectible or previously written off and recovered were $(1,126) and $17,135, respectively.

	Inventory

	Inventories are stated at the lower of cost or market value. Raw material inventory cost is determined on the first-in, first-out method. Costs of finished goods are determined by an actual cost method. We regularly review inventories on hand and write down the carrying value of our inventories for excess and potentially obsolete inventories based on historical usage and estimated future usage. In assessing the ultimate realization of our inventories, we are required to make judgments as to future demand requirements. As actual future demand or market conditions may vary from those projected by us, adjustment to inventories may be required.

	Prepaid Expenses and Deferred Charges

	From time to time fees are payable to the United States Food and Drug Administration (“FDA”) in connection with new drug applications submitted by us and annual prescription drug user fees (“PDUFA”). Such fees are being amortized ratably over the FDA’s prescribed fiscal period of twelve months ending September 30th. As of December 31, 2013 and 2012, the amount of prepaid PDUFA fees was nil and $73,582, respectively.

	Additionally, we amortize our insurance costs ratably over the term of each policy. Typically, our insurance policies are subject to renewal in July and October of each year.

	Notes Receivable

	Notes receivable are stated at unpaid principle balance. Interest on notes receivable is recognized over the term of the note and is calculated by the simple interest method on principle amounts outstanding. We estimate the collectability of our notes receivable. This estimate is based on similar evaluation criteria as used in estimating the collectability of our trade accounts receivable. Notes receivable are subject to an allowance for collection when it is probable that the balance, or a portion thereof, will not be collected. As of December 31, 2013 and 2012, the allowance for collection for our notes receivable was nil.

	Property, Equipment and Leasehold Improvements

	Property, equipment, and leasehold improvements are recorded at cost. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method. Estimated useful lives for property, equipment, and leasehold improvements categories are as follows:

	Furniture, fixtures, and laboratory equipment	7 years
	Computer and office equipment	5 years
	Computer software	3 years
	Leasehold improvements	Lease term

	Intangible Assets

	We expense internal patent and application costs as incurred because, even though we believe the patents and underlying processes have continuing value, the amount of future benefits to be derived from them are uncertain. Purchased patents are capitalized and amortized over the life of the patent.

	Impairment of Assets

	In accordance with the provisions of Accounting Standards Codification (“ASC”) Topic 350-30, Intangibles Other than Goodwill, our policy is to evaluate whether there has been a permanent impairment in the value of long-lived assets and certain identifiable intangibles when certain events have taken place that indicate the remaining unamortized balance may not be recoverable, or at least annually to determine the current value of the intangible asset. When factors indicate that the intangible assets should be evaluated for possible impairment, we use an estimate of undiscounted cash flows. Considerable management judgment is necessary to estimate the undiscounted cash flows. Accordingly, actual results could vary significantly from management’s estimates.

	Deferred Financing Costs

	We defer financing costs associated with the issuance of our convertible notes payable and amortize those costs over the period of the convertible notes using the effective interest method. In 2012, we incurred $200,000 of financing costs related to our convertible note payable with Inter-Mountain Capital Corp.

	During 2013 and 2012, we recorded amortization of approximately $74,000 and $39,000, respectively, of deferred financing costs. Other assets at December 31, 2013 and 2012 included net deferred financing costs of approximately of $87,000 and $161,000, respectively.

	Accrual for Clinical Study Costs

	We record accruals for estimated clinical study costs. Clinical study costs represent costs incurred by clinical research organizations, or CROs, and clinical sites. These costs are recorded as a component of research and development expenses. We analyze the progress of the clinical trials, including levels of patient enrollment and/or patient visits, invoices received and contracted costs when evaluating the adequacy of the accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual costs incurred may or may not match the estimated costs for a given accounting period. As of December 31, 2013 and 2012, the accrual for estimated clinical study costs was nil.

	Shipping and Handling Costs

	Shipping and handling costs incurred for product shipments are included in cost of goods sold.

	Income Taxes

	We use the liability method of accounting for income taxes pursuant to ASC Topic 740, Income Taxes. Under this method, deferred income taxes are recorded to reflect the tax consequences in future periods of temporary differences between the tax basis of assets and liabilities and their financial statement amounts at year-end.

Revenue Recognition and Deferred Revenue

License Fees

We recognize revenue from license payments not tied to achieving a specific performance milestone ratably during the period over which we are obligated to perform services. The period over which we are obligated to perform services is estimated based on available facts and circumstances. Determination of any alteration of the performance period normally indicated by the terms of such agreements involves judgment on management's part. License revenues with no specific performance criteria are recognized when received from our foreign licensee and their various foreign sub-licensees as there is no control by us over the various foreign sub-licensees and no performance criteria to which we are subject.

We recognize revenue from performance payments ratably, when such performance is substantially in our control and when we believe that completion of such performance is reasonably probable, over the period during which we estimate that we will complete such performance obligations. In circumstances where the arrangement includes a refund provision, we defer revenue recognition until the refund condition is no longer applicable unless, in our judgment, the refund circumstances are within our operating control and are unlikely to occur.

Substantive at-risk milestone payments, which are based on achieving a specific performance milestone when performance of such milestone is contingent on performance by others or for which achievement cannot be reasonably estimated or assured, are recognized as revenue when the milestone is achieved and the related payment is due, provided that there is no substantial future service obligation associated with the milestone.

Royalty Income

We receive royalty revenues under license agreements with a number of third parties that sell products based on technology we have developed or to which we have rights. The license agreements provide for the payment of royalties to us based on sales of the licensed products. We record these revenues based on estimates of the sales that occurred during the relevant period. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties we have been paid (adjusted for any changes in facts and circumstances, as appropriate).

We maintain regular communication with our licensees in order to gauge the reasonableness of our estimates. Differences between actual royalty revenues and estimated royalty revenues are reconciled and adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material based on actual amounts paid by licensees. As it relates to royalty income, there are no future performance obligations on our part under these license agreements. To the extent we do not have sufficient ability to accurately estimate revenue; we record it on a cash basis.

Product Sales

We recognize revenue and related costs from the sale of our products at the time the products are shipped to the customer. Provisions for returns, rebates, and discounts are established in the same period the related product sales are recorded.

We review the supply levels of our products sold to major wholesalers in the U.S., primarily by reviewing reports supplied by our major wholesalers and available volume information for our products, or alternative approaches. When we believe wholesaler purchasing patterns have caused an unusual increase or decrease in the sales of a major product compared with underlying demand, we disclose this in our product sales discussion if we believe the amount is material to the product sales trend; however, we are not always able to accurately quantify the amount of stocking or destocking. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.

We establish sales return accruals for anticipated product returns. We record the return amounts as a deduction to arrive at our net product sales. Consistent with Revenue Recognition accounting guidance, we estimate a reserve when the sales occur for future product returns related to those sales. This estimate is primarily based on historical return rates as well as specifically identified anticipated returns due to known business conditions and product expiry dates. Actual product returns have been nil over the past two years.

We establish sales rebate and discount accruals in the same period as the related sales. The rebate and discount amounts are recorded as a deduction to arrive at our net product sales. We base these accruals primarily upon our historical rebate and discount payments made to our customer segment groups and the provisions of current rebate and discount contracts.

Sponsored Research Income

Sponsored research income has no significant associated costs since it is being paid only for information pertaining to a specific research and development project in which the sponsor may become interested in acquiring products developed thereby. Payments received prior to our performance are deferred. Contract amounts are not recognized as revenue until the customer accepts or verifies the research has been completed.

Research and Development Expenses

Pursuant to ASC Topic 730, Research and Development, our research and development costs are expensed as incurred.

Research and development expenses include, but are not limited to, salaries and benefits, laboratory supplies, facilities expenses, preclinical development cost, clinical trial and related clinical manufacturing expenses, contract services, consulting fees and other outside expenses. The cost of materials and equipment or facilities that are acquired for research and development activities and that have alternative future uses are capitalized when acquired. There were no such capitalized materials, equipment or facilities for the years ended December 31, 2013 and 2012.

We may enter into certain research agreements in which we share expenses with a collaborator. We may also enter into other collaborations where we are reimbursed for work performed on behalf of our collaborative partners. We record the expenses for such work as research and development expenses. If the arrangement is a cost-sharing arrangement and there is a period during which we receive payments from the collaborator, we record payments by the collaborator for their share of the development effort as a reduction of research and development expense. If the arrangement is a reimbursement of research and development expenses, we record the reimbursement as sponsored research income.

Basic and Diluted Net Loss Per Common Share

In accordance with ASC Topic 260, Earnings per Share, basic earnings (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period increased to include potential dilutive common shares. The effect of outstanding stock options, restricted vesting common stock and warrants, when dilutive, is reflected in diluted earnings (loss) per common share by application of the treasury stock method. We have excluded all outstanding stock options, restricted vesting common stock and warrants from the calculation of diluted net loss per common share because all such securities are antidilutive for all periods presented.

Concentrations of Credit Risk

Concentration of credit risk with respect to financial instruments, consisting primarily of cash and cash equivalents, that potentially expose us to concentrations of credit risk due to the use of a limited number of banking institutions and due to maintaining cash balances in banks, which, at times, may exceed the limits of amounts insured by the Federal Deposit Insurance Corporation. During 2013, we utilized Bank of America, N.A. as our banking institution. At December 31, 2013 and December 31, 2012 our cash and cash equivalents totaled $5,119 and $21,549, respectively. We also invest cash in excess of immediate requirements in money market accounts, certificates of deposit, corporate commercial paper with high quality ratings, and U.S. government securities. These investments are not held for trading or other speculative purposes. We are exposed to credit risk in the event of default by these high quality corporations.

Concentration of credit risk with respect to trade accounts receivable are customers with balances that exceed 5% of total consolidated trade accounts receivable at December 31, 2013 and at December 31, 2012. As of December 31, 2013, two customers exceeded the 5% threshold, with 86% and 11%, respectively. Two customers exceeded the 5% threshold at December 31, 2012, with 77% and 13%, respectively. To reduce risk, we routinely assess the financial strength of our most significant customers and monitor the amounts owed to us, taking appropriate action when necessary. As a result, we believe that accounts receivable credit risk exposure is limited. We maintain an allowance for doubtful accounts, but historically have not experienced any significant losses related to an individual customer or group of customers.

Concentrations of Foreign Currency Risk

Substantially all of our revenue and expenses are denominated in U.S. dollars, although we expect our revenues in international territories to increase in the future. Certain of our licensing and distribution agreements in international territories are denominated in Euros. Currently, we do not employ forward contracts or other financial instruments to mitigate foreign currency risk. As our international operations grow, we may engage in hedging activities to hedge our exposure to foreign currency risk.

Fair Value of Financial Instruments

In accordance with portions of ASC Topic 820, Fair Value Measurements, certain assets and liabilities of the Company are required to be recorded at fair value. Fair value is determined based on the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants.

Our financial instruments, including cash, cash equivalents, accounts receivable, and accounts payable are carried at cost, which approximates their fair value because of the short-term maturity of these instruments. We believe that the carrying value of our other receivable, notes receivable and accrued interest, and convertible note payable balances approximates fair value based on a valuation methodology using the income approach and a discounted cash flow model.

Derivatives

We occasionally issue financial instruments that contain an embedded instrument. At inception, we assess whether the economic characteristics of the embedded derivative instrument are clearly and closely related to the economic characteristics of the financial instrument (host contract), whether the financial instrument that embodies both the embedded derivative instrument and the host contract is currently measured at fair value with changes in fair value reported in earnings, and whether a separate instrument with the same terms as the embedded instrument would meet the definition of a derivative instrument.

If the embedded derivative instrument is determined not to be clearly and closely related to the host contract, is not currently measured at fair value with changes in fair value reported in earnings, and the embedded derivative instrument would qualify as a derivative instrument, the embedded derivative instrument is recorded apart from the host contract and carried at fair value with changes recorded in current-period earnings.

We determined that all embedded items associated with financial instruments during 2013 and 2012 which qualify for derivative treatment, were properly separated from their host. As of December 31, 2013 and 2012, we did not have any derivative instruments.

THE_EFFECT_OF_RECENTLY_ISSUED_

THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS	12 Months Ended
	Dec. 31, 2013
THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS [Abstract]	'
THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS	'
	NOTE 3.	THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS

	In September 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2011-08, “Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment” (“ASU 2011-08”). ASU 2011-08 updated guidance on the periodic testing of goodwill for impairment. This guidance will allow companies to assess qualitative factors to determine if it is more-likely-than-not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment test required under current accounting standards. This new guidance is effective for fiscal years beginning after December 15, 2011; however, early adoption is permitted in certain circumstances. We adopted the provisions of ASU 2011-08 in the first quarter of 2012. The adoption of this update does not materially impact our financial statements.

	In June 2011, the FASB issued Accounting Standards Update No. 2011-05, “Comprehensive Income (Topic 220): Presentation of Comprehensive Income” (“ASU 2011-05”). ASU 2011-05 amended existing guidance by allowing only two options for presenting the components of net income and other comprehensive income: (1) in a single continuous financial statement of comprehensive income or (2) in two separate but consecutive financial statements, consisting of an income statement followed by a separate statement of other comprehensive income. Also, items that are reclassified from other comprehensive income to net income must be presented on the face of the financial statements. ASU No. 2011-05 requires retrospective application, and it is effective for fiscal years beginning after December 15, 2011. We adopted the provisions of ASU 2011-05 in the first quarter of 2012. The adoption of this update does not materially impact our financial statements.

	In May 2011, the FASB issued Accounting Standards Update No. 2011-04, “Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs” (“ASU 2011-04”). ASU 2011-04 generally provides a uniform framework for fair value measurements and related disclosures between U.S. generally accepted accounting principles and International Financial Reporting Standards. Additional disclosure requirements in the update include: (1) for Level 3 fair value measurements, quantitative information about unobservable inputs used, a description of the valuation processes used by the entity, and a qualitative discussion about the sensitivity of the measurements to changes in the unobservable inputs; (2) for an entity’s use of a nonfinancial asset that is different from the asset’s highest and best use, the reason for the difference; (3) for financial instruments not measured at fair value but for which disclosure of fair value is required, the fair value hierarchy level in which the fair value measurements were determined; and (4) the disclosure of all transfers between Level 1 and Level 2 of the fair value hierarchy. ASU 2011-04 was effective for interim and annual periods beginning on or after December 15, 2011. We adopted the provisions of ASU 2011-04 in the first quarter of 2012. The adoption of this update does not materially impact our financial statements.

	There are no other new accounting pronouncements adopted or enacted during the year ended December 31, 2013 that had, or are expected to have, a material impact on our financial statements.

SEGMENT_INFORMATION

SEGMENT INFORMATION	12 Months Ended
SEGMENT INFORMATION	Dec. 31, 2013
SEGMENT INFORMATION [Abstract]	'
SEGMENT INFORMATION	'
	NOTE 4.	SEGMENT INFORMATION

	We operate in one business segment: the research, development, and commercialization of pharmaceutical products. Our corporate headquarters in the United States collects product sales, licensing fees, royalties, and sponsored research revenues from our arrangements with external customers and licensees. Our entire business is managed by a single management team, which reports to the Chief Executive Officer.

	Our revenues are currently derived primarily from seven licensees for international activities and our domestic sales activities for Altrazeal®.

	Revenues per geographic area, along with relative percentages of total revenues, for the year ended December 31, are summarized as follows:

	Revenues		2013				%				2012		%
	Domestic		$	65,546				18	%		$	177,440		48	%
	International			305,022				82	%			193,154		52	%
	Total		$	370,568				100	%		$	370,594		100	%

	A significant portion of our revenues are derived from a few major customers. Customers with greater than 10% of total revenues, along with their relative percentage of total revenues, for the year ended December 31 are represented on the following table:

	Customers	Product		2013				2012
	Customer A	Altrazeal®			67	%			32	%
	Customer B	Altrazeal® Veterinary			-				14	%
	Customer C	Aphthasol®			-				13	%
	Total				67	%			59	%

OTHER_RECEIVABLE

OTHER RECEIVABLE	12 Months Ended
	Dec. 31, 2013
OTHER RECEIVABLE [Abstract]	'
OTHER RECEIVABLE	'
	NOTE 5.	OTHER RECEIVABLE

	On June 25, 2010, we entered into an acquisition and license agreement with Strakan International Limited and Zindaclin Limited, a subsidiary of Crawford Healthcare Limited, a pharmaceutical company based in England. Under the terms of the agreement, Zindaclin Limited will pay up to $5.1 million for the exclusive product rights to Zindaclin®, a zinc clindamycin product for the treatment of acne, which consideration will be shared equally by Strakan International Limited and us. Guaranteed payments of $1,050,000 were scheduled to be received by us, of which $550,000 occurred in 2010, $250,000 occurred in 2011, and $250,000 was to occur in June 2012. On March 22, 2012, we agreed to accept $220,000 for the early remittance of the final guaranteed payment, which was received prior to March 29, 2012.

NOTES_RECEIVABLE

NOTES RECEIVABLE	12 Months Ended
	Dec. 31, 2013
NOTES RECEIVABLE [Abstract]	'
NOTES RECEIVABLE	'
	NOTE 6.	NOTES RECEIVABLE

	On June 27, 2012, we entered into a Securities Purchase Agreement related to our issuance of a $2,210,000 Secured Convertible Note (the “June 2012 Note”), with Inter-Mountain Capital Corp., a Delaware corporation (“Inter-Mountain”). As part of the June 2012 Note transaction, we received $1,500,000 in the form of six promissory notes in favor of the Company, each in the principal amount of $250,000 (the “Investor Notes”) and each of which becomes due as the outstanding balance under the June 2012 Note is reduced to certain levels. On October 5, 2012, we and Inter-Mountain entered into a First Amendment to Buyer Trust Deed Note #1 (the “Trust Deed Note Amendment”) for the purpose of revising certain terms and conditions contained in the Buyer Trust Deed Note #1, to include receiving payments of $100,000, $100,000, and $50,000 on October 5, 2012, November 30, 2012, and December 31, 2012, respectively, and any interest thereon. As of December 31, 2013, we had $777,710 in notes receivable which is comprised of $687,500 for three Investor Notes and $90,210 for accrued interest thereon.

	Please refer to Note 12. for a more detailed description of the June 2012 Note transaction.

INVENTORY

INVENTORY	12 Months Ended
INVENTORY	Dec. 31, 2013
INVENTORY [Abstract]	'
INVENTORY	'
	NOTE 7.	INVENTORY

	As of December 31, 2013, our inventory was comprised of Altrazeal® finished goods, manufacturing costs incurred in the production of Altrazeal®, and raw materials. Inventories are stated at the lower of cost (first in, first out method) or market. We regularly review inventories on hand and write down the carrying value of our inventories for excess and potentially obsolete inventories based on historical usage and estimated future usage. In assessing the ultimate realization of our inventories, we are required to make judgments as to future demand requirements. As actual future demand or market conditions may vary from those projected by us, adjustment to inventories may be required. For the years ended December 31, 2013 and 2012, we wrote off approximately $60,000 and $88,000, respectively, in obsolete inventories.

	The components of inventory, at the different stages of production, consisted of the following at December 31:

	Inventory		2013		2012
	Finished goods		$	85,993	$	303,779
	Work-in-progress			299,464		190,794
	Raw materials			10,148		33,070
	Total		$	395,605	$	527,643

PROPERTY_EQUIPMENT_and_LEASEHO

PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS	12 Months Ended
PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS	Dec. 31, 2013
PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS [Abstract]	'
PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS	'
	NOTE 8.	PROPERTY, EQUIPMENT AND LEASEHOLD IMPROVEMENTS

	Property, equipment and leasehold improvements, net, consisted of the following at December 31:

	Property, equipment and leasehold improvements		2013			2012
	Laboratory equipment		$	424,888		$	424,888
	Manufacturing equipment			1,581,728			1,547,572
	Computers, office equipment, and furniture			140,360			140,360
	Computer software			4,108			4,108
	Leasehold improvements			95,841			95,841
				2,246,925			2,212,769
	Less: accumulated depreciation and amortization			(1,608,311	)		(1,367,234	)
	Property, equipment and leasehold improvements, net		$	638,614		$	845,535

	Depreciation expense on property, equipment, and leasehold improvements was $244,704 and $291,274 for the years ended December 31, 2013 and 2012, respectively.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
INTANGIBLE ASSETS	Dec. 31, 2013
INTANGIBLE ASSETS [Abstract]	'
INTANGIBLE ASSETS	'
	NOTE 9.	INTANGIBLE ASSETS

	Intangible assets are comprised of patents acquired in October 2005. Intangible assets, net consisted of the following at December 31:

	Intangible assets		2013			2012
	Patent - Amlexanox (Aphthasol®)		$	2,090,000		$	2,090,000
	Patent - Amlexanox (OraDisc™ A)			6,873,080			6,873,080
	Patent - OraDisc™			73,000			73,000
	Patent - Hydrogel nanoparticle aggregate			589,858			589,858
				9,625,938			9,625,938
	Less: accumulated amortization			(5,955,101	)		(5,479,953	)
	Intangible assets, net		$	3,670,837		$	4,145,985

	We performed an evaluation of our intangible assets for purposes of determining possible impairment as of December 31, 2013. Based upon recent market conditions and comparable market transactions for similar intangible assets, we determined that an income approach using a discounted cash flow model was an appropriate valuation methodology to determine each intangible asset’s fair value. The income approach converts future amounts to a single present value amount (discounted cash flow model). Our discounted cash flow models are highly reliant on various assumptions, including estimates of future cash flow (including long-term growth rates), discount rate, and expectations about variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows, all of which we consider level 3 inputs for determination of fair value. We believe we have appropriately reflected our best estimate of the assumptions that market participants would use in determining the fair value of our intangible assets at the measurement date. Upon completion of the evaluation, the fair value of our intangible assets exceeded the recorded remaining book value.

	Amortization expense for intangible assets was $475,148 and $476,450 for the years ended December 31, 2013 and 2012, respectively. The future aggregate amortization expense for intangible assets, remaining as of December 31, 2013, is as follows:

	Calendar Years		Future Amortization
	Calendar Years		Expense
	2014		$	475,148
	2015			475,148
	2016			476,450
	2017			475,148
	2018			475,148
	2019 & Beyond			1,293,795
	Total		$	3,670,837

INVESTMENT_IN_UNCONSOLIDATED_S

INVESTMENT IN UNCONSOLIDATED SUBSIDIARY	12 Months Ended
	Dec. 31, 2013
INVESTMENT IN UNCONSOLIDATED SUBSIDIARY [Abstract]	'
INVESTMENT IN UNCONSOLIDATED SUBSIDIARY	'
	NOTE 10.	INVESTMENT IN UNCONSOLIDATED SUBSIDIARY

	We use the equity method of accounting for investments in other companies that are not controlled by us and in which our interest is generally between 20% and 50% of the voting shares or we have significant influence over the entity, or both.

	On January 11, 2012, we executed a shareholders’ agreement for the establishment of Altrazeal Trading Ltd., a single purpose entity to be used for the exclusive marketing of Altrazeal® throughout the European Union, Australia, New Zealand, North Africa, and the Middle East. As a result of this transaction, we received a non-dilutable 25% ownership interest in Altrazeal Trading Ltd.

	Financial statements of Altrazeal Trading Ltd. for the years ended December 31, 2013 and 2012 have not been released to us, therefore, we have not included the effect of the financial activities of Altrazeal Trading Ltd in our financial statements for each year. We believe that our share of the cumulative losses of Altrazeal Trading Ltd for the years ended December 31, 2013 and 2012 would exceed the carrying value of our investment, therefore the equity method of accounting would be suspended for such years and no additional losses would be charged to operations.

	Based upon the unaudited financial statements provided by Altrazeal Trading Ltd. for the year ended December 31, 2012, our unrecorded share of Altrazeal Trading Ltd. losses for the year ended December 31, 2012 totaled $82,740.

	Summarized financial information for our investment in Altrazeal Trading Ltd. assuming 100% ownership is as follows:

	Altrazeal Trading Ltd.		2012
	Balance sheet
	Total assets		$	415,248
	Total liabilities		$	205,991
	Total stockholders’ equity		$	209,257
	Statement of operations
	Revenues		$	131,869
	Net (loss)		$	(330,961	)

	On October 19, 2012, we executed a shareholders’ agreement for the establishment of ORADISC GmbH, a single purpose entity to be used for the exclusive development and marketing of OraDisc™ erodible film technology products. We received a non-dilutable 25% ownership interest in ORADISC GmbH.

	As of December 31, 2013, ORADISC GmbH had not begun operations and accordingly the net book value of the investee assets had not been determined and there were no equity method investee gains or losses for the year ended December 31, 2013.

ACCRUED_LIABILITIES

ACCRUED LIABILITIES	12 Months Ended
ACCRUED LIABILITIES	Dec. 31, 2013
ACCRUED LIABILITIES [Abstract]	'
ACCRUED LIABILITIES	'
	NOTE 11.	ACCRUED LIABILITIES

	Accrued liabilities consisted of the following at December 31:

	Accrued Liabilities		2013		2012
	Accrued taxes – payroll		$	106,299	$	106,299
	Accrued compensation/benefits			148,683		213,005
	Accrued insurance payable			60,113		52,629
	Product rebates/returns			32		81
	Other			836		951
	Total accrued liabilities		$	315,963	$	372,965

CONVERTIBLE_DEBT

CONVERTIBLE DEBT	12 Months Ended
CONVERTIBLE DEBT	Dec. 31, 2013
CONVERTIBLE DEBT [Abstract]	'
CONVERTIBLE DEBT	'
	NOTE 12.	CONVERTIBLE DEBT

	Convertible Note – June 2012

	On June 27, 2012, we entered into a Securities Purchase Agreement (the “Purchase Agreement”), related to our issuance of the June 2012 Note with Inter-Mountain. The purchase price for the June 2012 Note was paid $500,000 at closing in cash and $1,500,000 in the form of six promissory notes in favor of the Company, each in the principal amount of $250,000 (the “Investor Notes”), each of which bears interest at the rate of 8.0% per annum, and each of which becomes due as the outstanding balance under the June 2012 Note is reduced to certain levels. The purchase price of the June 2012 Note also reflected a $200,000 original issue discount and $10,000 in attorney’s fees. The Purchase Agreement also includes representations and warranties, restrictive covenants, and indemnification provisions standard for similar transactions.

	The June 2012 Note bears interest at the rate of 8.0% per annum, with monthly installment payments of $83,333 commencing on the date that is the earlier of (i) thirty calendar days after the effective date of a registration statement registering the re-sale of the shares issuable upon conversion under the June 2012 Note or (ii) December 24, 2012, but in no event sooner than September 25, 2012. At our option, subject to certain volume, price, and other conditions, the monthly installment payments on the June 2012 Note may be paid in whole, or in part, in cash or in our common stock. If the monthly installment is paid in common stock, such shares being issued will be based on a price that is 80% of the average of the three lowest volume weighted average prices of the shares of common stock during the preceding twenty trading days. The percentage declines to 70% if the average of the three lowest volume weighted average prices of the shares of common stock during the preceding twenty trading days is less than $0.05.

	At the option of Inter-Mountain, the outstanding principal balance of the June 2012 Note may be converted into shares of our common stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations. The initial tranche was $710,000 and the six subsequent tranches are each $250,000, plus interest. At our option, the outstanding principal balance of the June 2012 Note, or a portion thereof, may be prepaid in cash at 120% of the amount elected to be prepaid. The June 2012 Note is secured by a Security Agreement pursuant to which we granted to Inter-Mountain a first-priority security interest in the assets held by the Company.

	Events of default under the June 2012 Note include failure to make required payments or to deliver shares upon conversion, the entry of a $100,000 judgment not stayed within 30 days, breach of representations or covenants under the transaction documents, various events associated with insolvency or failure to pay debts, delisting of our common stock, a restatement of financial statements, and a default under certain other agreements. In the event of default, the interest rate under the June 2012 Note increases to 18% and the June 2012 Note becomes callable at a premium. In addition, the holder has all remedies under law and equity, including foreclosing on our assets under a Security Agreement with Intermountain.

	As part of the convertible debt financing, Inter-Mountain also received a total of seven warrants (the “Warrants”) to purchase, if they all vest, an aggregate of 3,142,857 shares of common stock, which number of shares could increase based upon the terms and conditions of the Warrants. The Warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017. Warrants for 785,714, 392,857, 392,857, and 392,857 shares of common stock vested on June 27, 2012, December 31, 2012, February 26, 2013, and July 15, 2013, respectively. Each of the three remaining Warrants have terminated, as described below. For the year ended December 31, 2013, we issued 725,274 shares of common stock to Inter-Mountain for the cashless exercise of three warrants to purchase 1,571,428 shares of common stock.

	As part of the convertible debt financing, we entered into a Registration Rights Agreement whereby we agreed to prepare and file with the SEC a registration statement for the number of shares referred to therein no later than July 27, 2012 and to cause such registration statement to be declared effective no later than ninety days after such filing with the SEC and to keep such registration statement effective for a period of no less than one hundred and eighty days. The Registration Rights Agreement also grants Inter-Mountain piggy-back registration rights with respect to future offerings by the Company. In accordance with our obligations under the Registration Rights Agreement, we filed with the SEC a registration statement that was declared effective on July 31, 2012.

	On October 5, 2012, we and Inter-Mountain entered into a First Amendment to Buyer Trust Deed Note #1 for the purpose of revising certain terms and conditions contained in the Buyer Trust Deed Note #1, to include an updated schedule for the timing of certain payment obligations by Inter-Mountain contained therein.

	On January 22, 2014, we provided notice to Inter-Mountain of our election to exercise our rights under the June 2012 Note and to offset amounts we owed to Inter-Mountain against amounts it owed to us under the Investor Notes. Our notice provided that such deduction and offset occurred on January 22, 2014, that we will not incur the 120% prepayment premium with respect to amounts paid under the June 2012 Note as a result of the deduction and offset, that no warrants will become exercisable as a result of the offset, and that any warrants unvested as of January 22, 2014 shall immediately and automatically terminate. As a result, the outstanding amount owed under the June 2012 Note was reduced to approximately $317,000 as of January 22, 2014.

	On February 27, 2014 and on March 3, 2014, we received conversion notices from Inter-Mountain whereby we issued an aggregate of 435,502 shares of common stock for the final payment of approximately $152,000 due under the June 2012 Note.

	Convertible Note – July 2011

	On July 28, 2011, we completed a convertible debt financing for $125,000 with Mr. Kerry P. Gray, the Company’s Chairman, President, and Chief Executive Officer (the “July 2011 Note”). The July 2011 Note bears interest at the rate of 10.0% per annum, with annual payments of interest commencing on July 1, 2012. The full amount of principal and any unpaid interest will be due on July 28, 2014. The outstanding principal balance of the July 2011 Note may be converted into shares of the Company’s common stock, at the option of the note holder and at any time, at a conversion price of $1.08 per share or 115,741 shares of common stock. We may force conversion of the July 2011 Note if our common stock trades for a defined period of time at a price greater than $2.16. The July 2011 Note is collateralized by the grant of a security interest in the inventory, accounts receivables and capital equipment held by the Company. The securities issuable on conversion have not been registered under the Securities Act of 1933 and may not be sold absent registration or an applicable exemption from the registration requirements. As part of the convertible debt financing, Mr. Gray also received a warrant to purchase up to 34,722 shares of the Company’s common stock. The warrant has an exercise price of $1.08 per share and is exercisable at any time until July 28, 2016.

	On July 3, 2012, the Company and Mr. Gray entered into a Modification Agreement for the purpose of deferring the annual payment of interest due on July 1, 2012 of $11,542 until such time as Mr. Gray provides written notice to us with such notice being no less than 15 days prior to the relevant payment date. Moreover, the parties agreed that no Event of Default under the July 2011 Note occurred as a result of any failure by us to make the annual payment of interest due on July 1, 2012. Commencing on July 1, 2012, interest at the rate of 12.0% per annum accrued on the deferred interest payment of $11,542 until the relevant payment date. On September 5, 2013, we remitted to Mr. Gray the annual interest due on July 1, 2012 of $11,542 and accrued interest thereon of $1,643.

	On July 1, 2013, the Company and Mr. Gray entered into a Modification Agreement for the purpose of deferring the annual payment of interest due on July 1, 2013 of $12,501 until such time as Mr. Gray provides written notice to us with such notice being no less than 15 days prior to the relevant payment date. Moreover, the parties agreed that no Event of Default under the July 2011 Note occurred as a result of any failure by us to make the annual payment of interest due on July 1, 2013. Commencing on July 1, 2013, interest at the rate of 12.0% per annum accrued on the deferred interest payment of $12,501 until the relevant payment date. On October 28, 2013, we remitted to Mr. Gray the annual interest due on July 1, 2013 of $12,501 and accrued interest thereon of $492.

	Convertible Note – June 2011

	On June 13, 2011, we completed a $140,000 convertible debt financing with Mr. Gray (the “June 2011 Note”). The June 2011 Note bears interest at the rate of 10% per annum, with annual payments of interest commencing on July 1, 2012. The full amount of principal and any unpaid interest will be due on June 13, 2014. The outstanding principal balance of the June 2011 Note may be converted into shares of the Company’s common stock, at the option of the note holder and at any time, at a conversion price of $1.20 per share or 116,667 shares of common stock. We may force conversion of the convertible note if our common stock trades for a defined period of time at a price greater than $1.80. The June 2011 Note is collateralized by the grant of a security interest in the inventory, accounts receivables, and capital equipment held by the Company. The securities issuable on conversion have not been registered under the Securities Act of 1933 and may not be sold absent registration or an applicable exemption from the registration requirements. As part of the convertible debt financing, Mr. Gray also received a warrant to purchase up to 35,000 shares of the Company’s common stock. The warrant has an exercise price of $1.20 per share and is exercisable at any time until June 13, 2016.

	On July 3, 2012, the Company and Mr. Gray entered into a Modification Agreement for the purpose of deferring the annual payment of interest due on July 1, 2012 of $14,653 until such time as Mr. Gray provides written notice to us with such notice being no less than 15 days prior to the relevant payment date. Moreover, the parties agreed that no Event of Default under the June 2011 Note occurred as a result of any failure by us to make the annual payment of interest due on July 1, 2012. Commencing on July 1, 2012, interest at the rate of 12.0% per annum accrued on the deferred interest payment of $14,653 until the relevant payment date. On September 5, 2013, we remitted to Mr. Gray the annual interest due on July 1, 2012 of $14,653 and accrued interest thereon of $2,080.

	On July 1, 2013, the Company and Mr. Gray entered into a Modification Agreement for the purpose of deferring the annual payment of interest due on July 1, 2013 of $14,001 until such time as Mr. Gray provides written notice to us with such notice being no less than 15 days prior to the relevant payment date. Moreover, the parties agreed that no Event of Default under the June 2011 Note occurred as a result of any failure by us to make the annual payment of interest due on July 1, 2013. Commencing on July 1, 2013, interest at the rate of 12.0% per annum accrued on the deferred interest payment of $14,001 until the relevant payment date. On October 28, 2013, we remitted to Mr. Gray the annual interest due on July 1, 2013 of $14,001 and accrued interest thereon of $553.

	We account for convertible debt using specific guidelines in accordance with U.S. GAAP. We allocated the value of the proceeds received to the convertible instrument and to the warrant on a relative fair value basis. We calculated the fair value of the warrant issued with the convertible instrument using the Black-Scholes valuation method, using the same assumptions used for valuing employee stock options, except the contractual life of the warrant was used. Using the effective interest method, the allocated fair value was recorded as a debt discount and is being amortized over the expected term of the convertible debt to interest expense.

	On the date of issuance of the June 2011 Note, the July 2011 Note, and the June 2012 Note, no portion of the proceeds were attributable to a beneficial conversion feature since the conversion price of the June 2011 Note, the July 2011 Note, and the June 2012 Note exceeded the market price of the Company’s common stock.

	Information relating to our convertible notes payable is as follows:

															As of December 31, 2013
	Transaction		Initial			Interest			Maturity		Conversion				Principal				Unamortized				Carrying
			Principal			Rate			Date		Price (1)(2)				Balance				Debt				Value
			Amount																Discount
	June 2011 Note		$	140,000			10	%	6/13/14		$	1.2			$	140,000			$	1,780			$	138,220
	July 2011 Note			125,000			10	%	7/28/14		$	1.08				125,000				4,262				120,738
	June 2012 Note			2,210,000			8	%	3/27/15		$	0.35				1,093,638				205,539				888,099
	Total		$	2,475,000											$	1,358,638			$	211,581			$	1,147,057

	-1	The outstanding principal balance of the June 2011 Note and the July 2011 Note may be converted, at the option of Mr. Gray, into shares of common stock at a fixed conversion price of $1.20 per share and $1.08 per shares, respectively.
	-2	The outstanding principal balance of the June 2012 Note may be converted, at the option of Inter-Mountain, into shares of common stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations.

	The amount of interest cost recognized from our convertible notes payable was $157,027 and $117,711 for years ended December 31, 2013 and 2012, respectively.

	The amount of debt discount amortized from our convertible notes payable was $178,548 and $97,901 for years ended December 31, 2013 and 2012, respectively.

	The future minimum payments relating to our convertible notes payable, as of December 31, 2013, are as follows:

			Payments Due By Period
Transaction		Total			2014				2015				2016				2017				2018
June 2011 Note		$	140,000		$	140,000			$	-			$	-			$	-			$	-
July 2011 Note			125,000			125,000				-				-				-				-
June 2012 Note			1,093,638			1,093,638				-				-				-				-
Total		$	1,358,638		$	1,358,638			$	-			$	-			$	-			$	-

EQUITY_TRANSACTIONS

EQUITY TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
EQUITY TRANSACTIONS [Abstract]	'
EQUITY TRANSACTIONS	'
	NOTE 13.	EQUITY TRANSACTIONS

	Common Stock Transactions

	March 2013 Offering

	On March 14, 2013, we entered into a Securities Purchase Agreement (the “March SPA”) with Kerry P. Gray, the Company’s Chairman, President, and Chief Executive Officer and Terrance K. Wallberg, the Company’s Vice President and Chief Financial Officer (collectively, the “Investors”) relating to an equity investment of $440,000 by the Investors for 1,100,000 shares of our common stock, par value $0.001 per share (the “March Shares”) and warrants to purchase up to 660,000 shares of our common stock (the “March Warrants”) (the “March 2013 Offering”). Under the March SPA, the purchase and sale of the March Shares and March Warrants will take place at four closings over the next twelve months, with $88,000 being funded at the initial closing under the March SPA, $110,000 being funded on the four-month anniversary of the initial closing, $132,000 being funded on the eight-month anniversary of the initial closing, and $110,000 being funded on the one-year anniversary of the initial closing. The March Warrants have a fixed exercise price of $0.60 per share, become exercisable in tranches on each of the four funding dates, and expire on the five-year anniversary of the initial closing. On March 14, 2013, we closed the March 2013 Offering and received the initial funding tranche of $88,000 for the purchase of 220,000 shares of our common stock. We received subsequent funding tranches of $110,000, $132,000, and $110,000 for the purchase of 275,000, 330,000, and 275,000 shares of our common stock on July 15, 2013, November 14, 2013, and March 14, 2014, respectively.

	January 2013 Offering

	On December 21, 2012, we entered into a Securities Purchase Agreement (the “SPA”) with IPMD GmbH (“IPMD”) relating to an equity investment of $2,000,000 by IPMD for 5,000,000 shares of our common stock, par value $0.001 per share (the “Shares”) and warrants to purchase up to 3,000,000 shares of our common stock (the “Warrants”) (the “January 2013 Offering”). Under the SPA, the purchase and sale of the Shares and Warrants will take place at four closings over the next twelve months, with $400,000 being funded at the initial closing under the SPA, $500,000 being funded on the four-month anniversary of the initial closing, $600,000 being funded on the eight-month anniversary of the initial closing, and $500,000 being funded on the one-year anniversary of the initial closing. The Warrants have a fixed exercise price of $0.60 per share, become exercisable in tranches on each of the four funding dates, and expire on the one-year anniversary of the initial closing. On January 3, 2013, we closed the January 2013 Offering and received the initial funding tranche of $400,000 for the purchase of 1,000,000 shares of our common stock. We received subsequent funding tranches of $500,000, $300,000, $300,000, and $500,000 for the purchase of 1,250,000, 750,000, 750,000, and 1,250,000 shares of our common stock on May 7, 2013, September 6, 2013, October 24, 2013, and January 6, 2014 respectively.

	In the SPA, we also agree to appoint up to two directors nominated by IPMD to serve on our Board of Directors. On January 17, 2013, the Board of Directors of the Company appointed Helmut Kerschbaumer and Klaus Kuehne to each serve as a director of the Company. Messrs. Kerschbaumer and Kuehne are the designees of IPMD to serve on the Company’s Board of Directors pursuant to covenants in the SPA with IPMD.

	On January 3, 2014, the Warrants vested with respect to 3,000,000 shares of our common stock and were exercised by IPMD on that date pursuant to a Notice of Exercise, accepted by the Company, that provided for the issuance of 750,000 shares of common stock on each of January 31, 2014, February 28, 2014, March 31, 2014, and April 30, 2014 in exchange for the payment of $450,000 on each such date.

	On January 31, 2014, IPMD entered into an Assignment Agreement (the “Assignment Agreement”) with The Punch Trust (“TPT”) and Michael I. Sacks (“Sacks”) pursuant to which IPMD assigned to TPT and Sacks its rights and interests to purchase up to 3,000,000 shares of our common stock as detailed in the Warrants and the Notice of Exercise. Neither TPT nor Sacks paid any monetary consideration to IPMD in connection with the assignments under the Assignment Agreement.

	Concurrent with the assignment under the Assignment Agreement described above, ULURU, TPT, Sacks, and IPMD entered into an Implementation Agreement (the “Implementation Agreement”) pursuant to which we consented and agreed to the assignment of the Warrants to TPT and Sacks. We also agreed to issue and facilitate the delivery of the shares of Common Stock under the Warrants to TPT and Sacks upon their payment of the corresponding purchase price due under the Warrants. Under the terms of the Warrants, Sacks made payments of $450,000 on each of January 31, 2014 and February 28, 2014 and the Company issued 750,000 shares of Common Stock to him on each date, respectively. Of the 3,000,000 shares of Common Stock issuable under the Warrants, the Implementation Agreement provides for Sacks to acquire 2,000,000 shares (750,000 on each of January 31 and February 28 and 250,000 on each of March 31 and April 30) and TPT to acquire 1,000,000 shares (500,000 on each of March 31 and April 30).

	On January 31, 2014, we also entered into a Registration Rights Agreement with TPT and Sacks whereby we agreed to prepare and file with the SEC a registration statement for the number of shares referred to therein within sixty days after request and to use commercially reasonable efforts to cause such registration statement to be declared effective with the SEC and to keep such registration statement effective for a period of eighty days and, if necessary, such eighty day period being extended for up to sixty additional days.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
STOCKHOLDERS' EQUITY	Dec. 31, 2013
STOCKHOLDERS' EQUITY [Abstract]	'
STOCKHOLDERS' EQUITY	'
	NOTE 14.	STOCKHOLDERS’ EQUITY

	Common Stock

	As of December 31, 2013, we had 18,871,420 shares of common stock issued and outstanding. We issued 8,796,972 shares of common stock for the year ended December 31, 2013 comprised of 3,750,000 shares of common stock issued to IPMD pursuant to the January 2013 Offering, 825,000 shares of common stock issued to Messrs. Gray and Wallberg pursuant to the March 2013 Offering, 3,072,648 shares of common stock issued for installment payments due on the June 2012 Note with Inter-Mountain, 725,274 shares of common stock issued for the cashless exercise of warrants held by Inter-Mountain, 363,750 shares of common stock issued for consulting services, 60,000 shares of common stock issued in lieu of wages, and 300 shares of common stock issued for the vesting of certain restricted stock awards

	Preferred Stock

	As of December 31, 2013, we had no shares of Series A Preferred Stock (the "Series A Shares"). For the year ended December 31, 2013, we did not issue any new Series A Shares.

	On August 15, 2013, we provided notice to Ironridge Global III, LLC (“Ironridge”) for the redemption of all of the outstanding Series A Shares, a total of 65 Series A Shares. An affiliate of Ironridge, the issuer of promissory notes held by us, due 7.5 years from the issue date, in the principal amount of $969,000 (the “Notes”), agreed to accept the cancellation of the Notes held by us as full and final payment for the redemption amounts of the Series A Shares.

	Warrants

	The following table summarizes the warrants outstanding and the number of shares of common stock subject to exercise as of December 31, 2013 and the changes therein during the two years then ended:

			Number of Shares of Common Stock Subject to Exercise			Weighted – Average
			Number of Shares of Common Stock Subject to Exercise			Exercise Price
	Balance as of December 31, 2011			612,594		$	2.45

	Warrants issued			1,428,571			0.35
	Warrants exercised			-			-
	Warrants cancelled			-			-
	Balance as of December 31, 2012			2,041,165		$	0.98

	Warrants issued			4,445,714			0.56
	Warrants exercised (1)			(1,571,428	)		0.35
	Warrants cancelled			(250,000	)		0.35
	Balance as of December 31, 2013 (1)			4,665,451		$	0.82

	-1	As part of the June 2012 Note, Inter-Mountain received a total of seven warrants to purchase, if they all vest, an aggregate of 3,142,857 shares of common stock, which number of shares could increase based upon the terms and conditions of the warrants. The warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017. Warrants for 785,714, 392,857, 392,857, and 392,857 shares of common stock vested on June 27, 2012, December 31, 2012, February 26, 2013, and July 15, 2013, respectively, and three warrants for 1,571,428 shares of common stock have been exercised. For the purposes of this Table, only such net vested shares of common stock from the fourth warrant (392,857 shares) have been included, based upon an exercise price of $0.35 per share of common stock. On January 22, 2014, we elected to offset and deduct the three remaining Investor Notes from the principle amount due to Inter-Mountain under the June 2012 Note and as a result of the offset and deduction the three remaining warrants terminated.

	For the year ended December 31, 2013, we issued warrants to purchase up to an aggregate of 4,445,714 shares of our common stock which consisted of (i) a warrant issued to IPMD pursuant to the January 2013 Offering to purchase up to an aggregate of 3,000,000 shares of our common stock at an exercise price of $0.60 per share, (ii) a warrant issued to Kerry P. Gray pursuant to the March 2013 Offering to purchase up to an aggregate of 600,000 shares of our common stock at an exercise price of $0.60 per share, (iii) a warrant issued to Terrance K. Wallberg pursuant to the March 2013 Offering to purchase up to an aggregate of 60,000 shares of our common stock at an exercise price of $0.60 per share, and (iv) two warrants issued to Inter-Mountain to purchase up to an aggregate of 785,714 shares of our common stock at an exercise price of $0.35 per share. Also occurring during the year ended December 31, 2013 was the cashless exercise of warrants to purchase 1,571,428 shares of our common stock, at an exercise price of $0.35 per share, by Inter-Mountain and the cancellation of a warrant issued to NUWA Group LLC to purchase up to an aggregate of 250,000 shares of our common stock at an exercise price of $0.35 per share.

	Of the warrant shares subject to exercise as of December 31, 2013, expiration of the right to exercise is as follows:

	Date of Expiration		Number of Warrant Shares of Common Stock Subject to Expiration
	3-Jan-14			3,000,000
	23-Jul-14			69,050
	15-May-15			357,155
	13-Jun-16			35,000
	16-Jul-16			116,667
	28-Jul-16			34,722
	27-Jun-17			392,857
	14-Mar-18			660,000
	Total			4,665,451

EARNINGS_PER_SHARE

EARNINGS PER SHARE	12 Months Ended
EARNINGS PER SHARE	Dec. 31, 2013
EARNINGS PER SHARE [Abstract]	'
EARNINGS PER SHARE	'
	NOTE 15.	EARNINGS PER SHARE

	Basic and Diluted Net Loss Per Share

	In accordance with FASB Accounting Standards Codification (“ASC”) Topic 260, Earnings per Share, basic earnings (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period, increased to include potential dilutive common shares. The effect of outstanding stock options, restricted vesting common stock, convertible debt, convertible preferred stock, and warrants, when dilutive, is reflected in diluted earnings (loss) per common share by application of the treasury stock method. We have excluded all outstanding stock options, restricted vesting common stock, convertible debt, convertible preferred stock, and warrants from the calculation of diluted net loss per common share because all such securities are antidilutive for all periods presented.

	Shares used in calculating basic and diluted net loss per common share exclude these potential common shares as of December 31:

			31-Dec-13		31-Dec-12
	Warrants to purchase common stock (1)			4,665,451		2,041,165
	Stock options to purchase common stock			1,014,907		158,409
	Unvested restricted common stock			-		300
	Common stock issuable upon the assumed conversion of our convertible note payable from June 2012 (2)			3,124,680		5,617,974
	Common stock issuable upon the assumed conversion of our convertible notes payable from June 2011 and July 2011 (3)			253,315		368,637
	Common stock issuable upon the assumed conversion of our Series A preferred stock (4)(5)			-		1,002,634
	Total			9,058,353		9,189,119

	-1	As part of the June 2012 Note, Inter-Mountain received a total of seven warrants to purchase, if they all vest, an aggregate of 3,142,857 shares of common stock, which number of shares could increase based upon the terms and conditions of the warrants. The warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017. Warrants for 785,714, 392,857, 392,857, and 392,857 shares of common stock vested on June 27, 2012, December 31, 2012, February 26, 2013, and July 15, 2013, respectively, and three warrants for 1,571,428 shares of common stock have been exercised. For the purposes of this Table, only such net vested shares of common stock from the fourth warrant (392,857 shares) have been included, based upon an exercise price of $0.35 per share of common stock. On January 22, 2014, we elected to offset and deduct the three remaining Investor Notes from the principle amount due to Inter-Mountain under the June 2012 Note and as a result of the offset and deduction the three remaining warrants terminated.
	-2	The outstanding principal balance and the accrued and unpaid interest of the June 2012 Note may be converted, at the option of Inter-Mountain, into shares of common stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations. For the purposes of this Table, we have assumed a conversion price of $0.35 per share and no ownership limitations.
	-3	The outstanding principal balance of the June 2011 Note and the July 2011 Note may be converted, at the option of Mr. Gray, into shares of common stock at a fixed conversion price of $1.20 per share and $1.08 per share, respectively. The accrued and unpaid interest for each convertible note payable may be converted, at the option of Mr. Gray, into shares of common stock at a conversion price based upon the average of the five trading days prior to the payment date, which for the purposes of this Table we have assumed to be December 31, 2013.
	-4	The outstanding Series A preferred stock and the accrued and unpaid dividends thereon are convertible into shares of the Company’s common stock at the Company’s option at any time after six-months from the date of issuance of the Series A preferred stock. The conversion price for the holder is fixed at $0.70 per share with no adjustment mechanisms, resets, ratchets, or anti-dilution covenants other than the customary adjustments for stock splits. For the purposes of this Table, we have assumed a conversion price of $0.70 per share.
	-5	On August 15, 2013, we provided notice to Ironridge for the redemption of all of our Series A Shares held by Ironridge, a total of 65 Series A Shares. An affiliate of Ironridge, the issuer of promissory notes held by us, due 7.5 years from the issue date, in the principal amount of $969,000, agreed to accept the cancellation of the promissory notes held by us as full and final payment for the redemption amounts of the Series A Shares.

SHARE_BASED_COMPENSATION

SHARE BASED COMPENSATION	12 Months Ended
SHARE BASED COMPENSATION	Dec. 31, 2013
SHARE BASED COMPENSATION [Abstract]	'
SHARE BASED COMPENSATION	'
	NOTE 16.	SHARE BASED COMPENSATION

	The Company’s share-based compensation plan, the 2006 Equity Incentive Plan (“Incentive Plan”), is administered by the compensation committee of the Board of Directors, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the award.

	Our Board of Directors granted the following incentive stock option awards to executives or employees and nonstatutory stock option awards to directors or non-employees for the years ended December 31:

			2013				2012(1)
	Incentive Stock Options
	Quantity			232,500				-
	Weighted average fair value per share		$	0.24				-
	Fair value		$	56,112				-

	Nonstatutory Stock Options
	Quantity			735,000				-
	Weighted average fair value per share		$	0.24				-
	Fair value		$	177,388				-

	-1	The Company did not award any share-based compensation for the year ended December 31, 2012.

	We account for share-based compensation under ASC Topic 718, Stock Compensation, which requires the measurement and recognition of compensation expense in the financial statements for all share-based payment awards made to employees, consultants, and directors is measured based on the estimated fair value of the award on the grant date. We use the Black-Scholes option-pricing model to estimate the fair value of share-based awards with the following weighted average assumptions for the years ended December 31:

			2013				2012 (4)
	Incentive Stock Options
	Expected volatility (1)			103.55	%			-
	Risk-fee interest rate % (2)			0.81	%			-
	Expected term (in years)			5				-
	Dividend yield (3)			-				-
				-
	Nonstatutory Stock Options
	Expected volatility (1)			103.55	%			-
	Risk-fee interest rate % (2)			0.81	%			-
	Expected term (in years)			5				-
	Dividend yield (3)			-				-

	-1	Expected volatility assumption was based upon a combination of historical stock price volatility measured on a daily basis and an estimate of expected future stock price volatility.
	-2	Risk-free interest rate assumption is based upon U.S. Treasury bond interest rates appropriate for the term of the stock options.
	-3	The Company does not currently intend to pay cash dividends, thus has assumed a 0% dividend yield.
	-4	The Company did not award any share-based compensation for the year ended December 31, 2012.

	Stock Options (Incentive and Nonstatutory)

	The following table summarizes share-based compensation related to stock options for the years ended December 31:

			2013				2012
	Research and development		$	16,863			$	6,280
	Selling, general and administrative			64,076				31,617
	Total share-based compensation expense		$	80,939			$	37,897

	At December 31, 2013, the balance of unearned share-based compensation to be expensed in future periods related to unvested stock option awards, as adjusted for expected forfeitures, is approximately $152,443. The period over which the unearned share-based compensation is expected to be recognized is approximately twenty seven months.

	The following table summarizes the stock options outstanding and the number of shares of common stock subject to exercise as of December 31, 2013 and the changes therein during the two years then ended:

			Stock Options				Weighted Average Exercise Price per Share
	Outstanding as of December 31, 2011			287,745			$	16.89
	Granted			-				-
	Forfeited/cancelled			(129,336	)			22.49
	Exercised			-				-
	Outstanding as of December 31, 2012			158,409				12.32
	Granted			967,500				0.33
	Forfeited/cancelled			(111,002	)			1.03
	Exercised			-				-
	Outstanding as of December 31, 2013			1,014,907			$	2.12

The following table presents the stock option grants outstanding and exercisable as of December 31, 2013:

Options Outstanding										Options Exercisable
Stock Options Outstanding				Weighted Average Exercise Price per Share				Weighted Average Remaining Contractual Life in Years		Stock		Weighted Average Exercise Price per Share
										Options
										Exercisable
	892,500			$	0.33				9.2		197,500	$	0.33
	53,334				2.38				4.5		46,668		2.36
	30,002				14.4				3.3		30,002		14.4
	39,071				33.35				3.8		39,071		33.35
	1,014,907			$	2.12				8.6		313,241	$	6.1

Restricted Stock Awards

Restricted stock awards, which typically vest over a period of six months to five years, are issued to certain key employees and are subject to forfeiture until the end of an established restriction period. We utilize the market price on the date of grant as the fair market value of restricted stock awards and expense the fair value on a straight-line basis over the vesting period.

The following table summarizes share-based compensation related to restricted stock awards for the years ended December 31:

		2013				2012
Research and development		$	444			$	3,762
Selling, general and administrative			547				4,535
Total share-based compensation expense		$	991			$	8,297

At December 31, 2013, the balance of unearned share-based compensation to be expensed in future periods related to restricted stock awards, as adjusted for expected forfeitures, is nil.

The following table summarizes the non-vested restricted stock awards outstanding and the number of shares of common stock subject to potential issue as of December 31, 2013 and the changes therein during the two years then ended:

		Restricted Stock				Weighted Average Grant Date Fair Value
Outstanding as of December 31, 2011			1,096			$	41.47
Granted			-				-
Forfeited/cancelled			(97	)			34.59
Exercised/issued			(699	)			45.39
Outstanding as of December 31, 2012			300			$	34.59
Granted			-				-
Forfeited/cancelled			-				-
Exercised/issued			(300	)			34.59
Outstanding as of December 31, 2013			-			$	-

Summary of Plans

2006 Equity Incentive Plan

In March 2006, our Board adopted and our stockholders approved our Equity Incentive Plan, which initially provided for the issuance of up to 133,333 shares of our common stock pursuant to stock option and other equity awards. At the annual meetings of the stockholders held on May 8, 2007, December 17, 2009, June 15, 2010, June 14, 2012, and on June 13, 2013, our stockholders approved amendments to the Equity Incentive Plan to increase the total number of shares of common stock issuable under the Equity Incentive Plan pursuant to stock options and other equity awards by 266,667 shares, 200,000 shares, 200,000 shares, 400,000 shares, and 600,000 shares, respectively, to a total of 1,800,000 shares.

In December 2006, we began issuing stock options to employees, consultants, and directors. The stock options issued generally vest over a period of one to four years and have a maximum contractual term of ten years. In January 2007, we began issuing restricted stock awards to our employees. Restricted stock awards generally vest over a period of six months to five years after the date of grant. Prior to vesting, restricted stock awards do not have dividend equivalent rights, do not have voting rights and the shares underlying the restricted stock awards are not considered issued and outstanding. Shares of common stock are issued on the date the restricted stock awards vest.

As of December 31, 2013, we had granted options to purchase 1,376,167 shares of common stock since the inception of the Equity Incentive Plan, of which 1,014,907 were outstanding at a weighted average exercise price of $2.12 per share, and we had granted awards for 68,616 shares of restricted stock since the inception of the Equity Incentive Plan, of which none were outstanding. As of December 31, 2013, there were 715,647 shares that remained available for future grants under our Equity Incentive Plan.

EMPLOYMENT_BENEFIT_PLAN

EMPLOYMENT BENEFIT PLAN	12 Months Ended
	Dec. 31, 2013
EMPLOYMENT BENEFIT PLAN [Abstract]	'
EMPLOYMENT BENEFIT PLAN	'
	NOTE 17.	EMPLOYMENT BENEFIT PLAN

	We maintain a defined contribution or 401(k) Plan for our qualified employees. Participants may contribute a percentage of their compensation on a pre-tax basis, subject to a maximum annual contribution imposed by the Internal Revenue Code. We may make discretionary matching contributions as well as discretionary profit-sharing contributions to the 401(k) Plan. Our contributions to the 401(k) Plan are made in cash and vest immediately. The Company’s common stock is not an investment option available to participants in the 401(k) Plan. We contributed $20,917 and $25,085 to the 401(k) Plan during the years ended December 31, 2013 and 2012, respectively.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
FAIR VALUE MEASUREMENTS	Dec. 31, 2013
FAIR VALUE MEASUREMENTS [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	NOTE 18.	FAIR VALUE MEASUREMENTS

	In accordance with ASC Topic 820, Fair Value Measurements, (“ASC Topic 820”) certain assets and liabilities of the Company are required to be recorded at fair value. Fair value is determined based on the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants. The guidance in ASC Topic 820 also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimized the use of unobservable inputs by requiring that the most observable inputs be used when available.

	Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on our market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

	The three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies, is as follows:

		Level 1	—	Valuations based on quoted prices (unadjusted) for identical assets or liabilities in active markets.

		Level 2	—	Valuations based on observable inputs other than quoted prices in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and other inputs that are observable or can be corroborated by observable market data.
		Level 2	—

		Level 3	—	Valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants.
		Level 3	—

	Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurements. We review the fair value hierarchy classification on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.

	Our financial instruments, including cash, cash equivalents, accounts receivable, and accounts payable are carried at cost, which approximates their fair value because of the short-term maturity of these instruments. We believe that the carrying value of our notes receivable and accrued interest and convertible note payable balances approximates fair value based on a valuation methodology using the income approach and a discounted cash flow model.

	The fair value of our financial instruments consisted of the following at December 31:

	Description		2013		2012
	Assets:
	Notes receivable and accrued interest		$	777,710	$	1,302,220

	Liabilities:
	Convertible note – June 2011		$	138,220	$	134,154
	Convertible note – July 2011		$	120,738	$	113,084
	Convertible note – June 2012		$	888,099	$	1,593,924

INCOME_TAXES

INCOME TAXES	12 Months Ended
INCOME TAXES	Dec. 31, 2013
INCOME TAXES [Abstract]	'
INCOME TAXES	'
	NOTE 19.	INCOME TAXES

	There was no current federal tax provision or benefit recorded for any period since inception, nor were there any recorded deferred income tax assets, as such amounts were completely offset by valuation allowances. Deferred tax assets as of December 31, 2013, of $18,344,933 were reduced to zero, after considering the valuation allowance of $18,344,933, since there is no assurance of future taxable income. As of December 31, 2013 we have consolidated net operating loss carryforwards (“NOL”) and research credit carryforwards for income tax purposes of approximately $49,550,149 and $511,949, respectively.

	The following are the consolidated operating loss carryforwards and research credit carryforwards that will begin expiring as follows:

	Calendar Years		Consolidated Operating Loss Carryforwards			Research Activities
	Calendar Years		Consolidated Operating Loss Carryforwards			Carryforwards
	2021		$	34,248		$	-
	2023			95,666			-
	2024			910,800			13,584
	2025			1,687,528			21,563
	2026			11,950,281			60,797
	2027			3,431,365			85,052
	2028			8,824,940			139,753
	2029			6,889,761			81,940
	2030			5,113,583			41,096
	2031			3,728,626			43,592
	2032			3,695,792			8,690
	2033			3,187,559			15,882
	Total		$	49,550,149		$	511,949

	The Tax Reform Act of 1986 contains provisions, which limit the amount of NOL and tax credit carryforwards that companies may utilize in any one year in the event of cumulative changes in ownership over a three-year period in excess of 50%. Since the effective date of the Tax Reform Act of 1986, the Company has completed significant share issuances in 2003 and 2006 which may significantly limit our ability to utilize our NOL and tax credit carryforwards against taxable earnings in future periods. Ownership changes in future periods may place additional limits on our ability to utilize NOLs and tax credit carryforwards.

	An analysis of the tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2013 and 2012 are as follows:

			2013			2012
	Deferred tax assets:
	Net operating loss carryforwards		$	17,657,746		$	16,549,134
	Intangible assets			247,248			305,552
	Other			512,286			502,732
	Total gross deferred tax assets			18,417,280			17,357,418

	Deferred tax liabilities:
	Property and equipment			72,347			77,839
	Total gross deferred tax liabilities			72,347			77,839

	Net total of deferred assets and liabilities			18,344,933			17,279,579
	Valuation allowance			(18,344,933	)		(17,279,579	)
	Net deferred tax assets		$	---		$	---

	The valuation allowance increased by $1,065,354 and $1,225,683 in 2013 and 2012, respectively.

	The following is a reconciliation of the expected statutory federal income tax rate to our actual income tax rate for the years ended December 31:

			2013			2012
	Expected income tax (benefit) at federal statutory tax rate -35%		$	( 1,137,320	)	$	( 1,309,975	)

	Permanent differences			21,754			16,500
	Research tax credits			(15,882	)		(8,690	)
	Amortization of deferred start up costs			-			-
	Valuation allowance			1,131,448			1,302,165
	Income tax expense		$	-		$	-

	Effective January 1, 2007, we adopted ASC Topic 740, Accounting for Uncertainty in Income Taxes. ASC Topic 740 is a comprehensive model for how a company should recognize, measure, present, and disclose in its financial statements uncertain tax positions that we have taken or expects to take on a tax return. If an income tax position exceeds a more likely than not (greater than 50%) probability of success upon tax audit, we will recognize an income tax benefit in its financial statements. Additionally, companies are required to accrue interest and related penalties, if applicable, on all tax exposures consistent with jurisdictional tax laws. We did not have any unrecognized tax benefits and there was no effect on our financial condition or results of operations as a result of implementing ASC Topic 740.

	Federal income tax returns for fiscal years 2010 through 2013 remain open and subject to examination by the Internal Revenue Service. We file and remit state income taxes in various states where we have determined it is required to file state income taxes. Our filings with those states remain open for audit for the fiscal years 2010 through 2013.

	We do not believe there will be any material changes in our unrecognized tax positions over the next 12 months. Our policy is that we recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of the date of adoption of ASC 740, we did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the period. The liability for unrecognized tax benefits is zero at December 31, 2013 and 2012.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
COMMITMENTS AND CONTINGENCIES	Dec. 31, 2013
COMMITMENTS AND CONTINGENCIES [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 20.	COMMITMENTS AND CONTINGENCIES

	Operating Leases

	On January 31, 2006 we entered into a lease agreement for office and laboratory space in Addison, Texas. The lease commenced on April 1, 2006 and originally continued until April 1, 2013. The lease required a minimum monthly lease obligation of $9,330, which was inclusive of monthly operating expenses, until April 1, 2011 and at such time increased to $9,776, which was inclusive of monthly operating expenses. On February 22, 2013, we executed an Amendment to Lease Agreement (the “Lease Amendment”) that renewed and extended our lease until March 31, 2015. The Lease Amendment requires a minimum monthly lease obligation of $9,193, which is inclusive of monthly operating expenses, until March 31, 2014 and at such time, will increase to $9,379, which is inclusive of monthly operating expenses.

	On December 10, 2010 we entered into a lease agreement for certain office equipment. The lease, which commenced on February 1, 2011 and continues until February 1, 2015, requires a minimum lease obligation of $744 per month.

	The future minimum lease payments under the 2013 office lease and the 2010 equipment lease are as follows as of December 31, 2013:

	Calendar Years		Future Lease Expense
	2014		$	120,917
	2015			28,881
	2016			-
	2017			-
	2018			-
	Total		$	149,798

	Rent expense for our operating leases amounted to $116,488 and $130,065 for the years ended December 31, 2013 and 2012, respectively.

	Indemnification

	In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future, but have not yet been made. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record charges in the future as a result of these indemnification obligations.

	In accordance with our restated articles of incorporation and our amended and restated bylaws, we have indemnification obligations to our officers and directors for certain events or occurrences, subject to certain limits, while they are serving at our request in their respective capacities. There have been no claims to date and we have a director and officer insurance policy that enables us to recover a portion of any amounts paid for future potential claims. We have also entered into contractual indemnification agreements with each of our officers and directors.

	Separation Agreement

	As of December 31, 2013, we continue to be a party to a separation agreement with Kerry P. Gray, dated March 9, 2009. Mr. Gray currently serves as our Chairman of the Board, Chairman of the Board’s Executive Committee, Chief Executive Officer, and President. Pursuant to the terms of the separation agreement, we provide or have provided, as applicable, certain benefits to Mr. Gray, including: (i) payments totaling $400,000 during the initial 12 month period following March 9, 2009; (ii) commencing March 1, 2010 and continuing for a period of forty-eight (48) months, a payment of $12,500 per month; (iii) full acceleration of all vesting schedules for all outstanding Company stock options and shares of restricted stock of the Company held by Mr. Gray, with all such Company stock options exercisable by Mr. Gray having expired on March 1, 2012, provided that Mr. Gray forfeited 20,000 stock options previously held by him; and (iv) for a period of twenty-four (24) months following March 9, 2009 we were required to maintain and provide coverage under Mr. Gray’s existing health coverage plan. The separation agreement contains a mutual release of claims, certain stock lock-up provisions, and other standard provisions.

	Related Party Transactions and Concentration

	On January 17, 2013, the Board of Directors of the Company appointed Helmut Kerschbaumer and Klaus Kuehne to each serve as a director of the Company. Mr. Kerschbaumer currently serves as a director of IPMD, Altrazeal Trading GmbH, Altrazeal AG, and Melmed Holding AG (collectively, the Altrazeal Distributors”) and Mr. Kuehne currently serves as a director of Altrazeal AG. In such capacities, Mr. Kerschbaumer may be considered, either singularly or collectively, to have control of, and make investment and business decisions on behalf of the Altrazeal Distributors and Mr. Kuehne may be considered, either singularly of collectively, to have control of, and make investment and business decisions on behalf of Altrazeal AG.

	Currently, we are party to License and Supply Agreements with Altrazeal Trading GmbH, Altrazeal AG, and Melmed Holding AG for the marketing and distribution of Altrazeal in various international territories. On December 21, 2012, we entered into a Securities Purchase Agreement with IPMD as described in more detail in Note 12.

	For the years ended December 31, 2013 and 2012, the Company recorded revenues, in approximate numbers, of $281,000 and $117,000, respectively, with Altrazeal Distributors, which represented 76% and 32% of our total revenues. As of December 31, 2013 and December 31, 2012, Altrazeal Distributors had an outstanding accounts receivable, in approximate numbers, of $174,000 and $101,000, respectively, which represented 97% and 77% of our total outstanding accounts receivables.

	Related Party Obligations

	Since 2011, our named executive officers and certain key executives have temporarily deferred portions of their compensation as part of a plan to conserve the Company’s cash and financial resources.

	As of December 31, 2013, the following table summarizes the compensation temporarily deferred since 2011:

	Name		2013			2012		2011		Total
	Kerry P. Gray (1)		$	(91,000	)	$	220,673	$	140,313	$	269,986
	Terrance K. Wallberg			(35,769	)	$	24,230	$	36,539	$	25,000
	Key executives			(20,000	)	$	27,253	$	20,986	$	28,239
	Total		$	(146,739	)	$	272,156	$	197,838	$	323,225

		-1	During 2013, Mr. Gray temporarily deferred compensation of $221,500 which consisted of $11,500 earned pursuant to a Separation Agreement and $210,000 for his duties as Chairman of the Executive Committee of the Company’s Board of Directors. During 2013, Mr. Gray was also repaid $312,500 of temporarily deferred compensation, of which $300,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.

	For the years ended December 31, 2013 and 2012, the Company’s obligation for temporarily deferred compensation was $323,225, of which $207,500 was included in accounts payable and $115,725 was included in accrued liabilities, and $469,994, of which $310,000 was included in accounts payable and $159,994 was included in accrued liabilities, respectively.

	Contingent Milestone Obligations

	We are subject to paying Access Pharmaceuticals, Inc. (“Access”) for certain milestones based on our achievement of certain annual net sales, cumulative net sales, and/or our having reached certain defined technology milestones including licensing agreements and advancing products to clinical development. As of December 31, 2013, the future milestone obligations that we are subject to paying Access, if the milestones related thereto are achieved, total $4,750,000. Such milestones are based on total annual sales of 20 and 40 million dollars of certain products, annual sales of 20 million dollars of any one certain product, and cumulative sales of such products of 50 and 100 million dollars.

	On March 7, 2008, we terminated the license agreement with ProStrakan Ltd. for Amlexanox-related products in the United Kingdom and Ireland. As part of the termination, we agreed to pay ProStrakan Ltd. a royalty of 30% on any future payments received by us from a new licensee in the United Kingdom and Ireland territories, up to a maximum of $1,400,000. On November 17, 2008, we entered into a licensing agreement for Amlexanox-related product rights to the United Kingdom and Ireland territories with MEDA AB.

LEGAL_PROCEEDINGS

LEGAL PROCEEDINGS	12 Months Ended
	Dec. 31, 2013
LEGAL PROCEEDINGS [Abstract]	'
LEGAL PROCEEDINGS	'
	NOTE 21.	LEGAL PROCEEDINGS

	From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. We are not currently a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on the results of our operations or financial position. There are no material proceedings to which any director, officer or any of our affiliates, any owner of record or beneficially of more than five percent of any class of our voting securities, or any associate of any such director, officer, our affiliates, or security holder, is a party adverse to us or our consolidated subsidiary or has a material interest adverse thereto.

SELECTED_QUARTERLY_FINANCIAL_D

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)	12 Months Ended
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)	Dec. 31, 2013
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) [Abstract]	'
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)	'
	NOTE 22.	SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

	The following table contains condensed information from the Company’s Consolidated Statements of Operations for each quarter of the years ended December 31, 2013 and 2012. We have derived this data from its unaudited quarterly financial statements. We believe that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.

			First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	2013
	Revenues		$	102,044		$	28,884		$	110,580		$	129,060
	Costs and expenses			649,413			744,932			743,033			880,888
	Operating (loss)			(547,369	)		(716,048	)		(632,453	)		(751,828	)
	Other income (expense)			(109,221	)		(106,737	)		(110,816	)		(106,442	)
	Net (loss)		$	(656,590	)	$	(822,785	)	$	(743,269	)	$	(858,270	)
	Less preferred stock dividends			(12,021	)		(12,154	)		(6,061	)		---
	Net (loss) allocable to common stockholders		$	(668,611	)	$	(834,939	)	$	(749,330	)	$	(858,270	)

	Basic and diluted net (loss) per common share		$	(0.06	)	$	(0.06	)	$	(0.05	)	$	(0.04	)

	2012
	Revenues		$	60,005		$	56,211		$	88,922		$	165,456
	Costs and expenses			879,717			884,289			837,149			1,034,259
	Operating (loss)			(819,712	)		(828,078	)		(748,227	)		(868,803	)
	Other income (expense)			(23,697	)		(30,068	)		(103,498	)		(109,266	)
	Net (loss)		$	(843,409	)	$	(858,146	)	$	(851,725	)	$	(978,069	)
	Less preferred stock dividends			(10,726	)		(12,154	)		(12,288	)		(12,288	)
	Net (loss) allocable to common stockholders		$	(854,135	)	$	(870,300	)	$	(864,013	)	$	(990,357	)

	Basic and diluted net (loss) per common share		$	(0.11	)	$	(0.11	)	$	(0.10	)	$	(0.10	)

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
SUBSEQUENT EVENTS [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 23.	SUBSEQUENT EVENTS

	Convertible Note – June 2012

	On January 22, 2014, we provided notice to Inter-Mountain of our election to exercise our rights under the June 2012 Note and to offset amounts we owed to Inter-Mountain against amounts it owed to us under the Investor Notes. Our notice provided that such deduction and offset occurred on January 22, 2014, that we will not incur the 120% prepayment premium with respect to amounts paid under the June 2012 Note as a result of the deduction and offset, that no warrants will become exercisable as a result of the offset, and that any warrants unvested as of January 22, 2014 shall immediately and automatically terminate. As a result, the outstanding amount owed under the June 2012 Note was reduced to $317,029 as of January 22, 2014.

	On February 27, 2014 and on March 3, 2014, we received conversion notices from Inter-Mountain whereby we issued an aggregate of 435,502 shares of common stock for the final payment of $152,426 due under the June 2012 Note.

	January 2013 Offering

	On January 3, 2014, the Warrants vested with respect to 3,000,000 shares of our common stock and were exercised by IPMD on that date pursuant to a Notice of Exercise, accepted by the Company, that provided for the issuance of 750,000 shares of common stock on each of January 31, 2014, February 28, 2014, March 31, 2014, and April 30, 2014 in exchange for the payment of $450,000 on each such date.

	On January 31, 2014, IPMD entered into an Assignment Agreement (the “Assignment Agreement”) with The Punch Trust (“TPT”) and Michael I. Sacks (“Sacks”) pursuant to which IPMD assigned to TPT and Sacks its rights and interests to purchase up to 3,000,000 shares of our common stock as detailed in the Warrants and the Notice of Exercise. Neither TPT nor Sacks paid any monetary consideration to IPMD in connection with the assignments under the Assignment Agreement.

	Concurrent with the assignment under the Assignment Agreement described above, ULURU, TPT, Sacks, and IPMD entered into an Implementation Agreement (the “Implementation Agreement”) pursuant to which we consented and agreed to the assignment of the Warrants to TPT and Sacks. We also agreed to issue and facilitate the delivery of the shares of Common Stock under the Warrants to TPT and Sacks upon their payment of the corresponding purchase price due under the Warrants. Under the terms of the Warrants, Sacks made payments of $450,000 on each of January 31, 2014 and February 28, 2014 and the Company issued 750,000 shares of Common Stock to him on each date, respectively. Of the 3,000,000 shares of Common Stock issuable under the Warrants, the Implementation Agreement provides for Sacks to acquire 2,000,000 shares (750,000 on each of January 31 and February 28 and 250,000 on each of March 31 and April 30) and TPT to acquire 1,000,000 shares (500,000 on each of March 31 and April 30).

	On January 31, 2014, we also entered into a Registration Rights Agreement with TPT and Sacks whereby we agreed to prepare and file with the SEC a registration statement for the number of shares referred to therein within sixty days after request and to use commercially reasonable efforts to cause such registration statement to be declared effective with the SEC and to keep such registration statement effective for a period of eighty days and, if necessary, such eighty day period being extended for up to sixty additional days.

COMPANY_OVERVIEW_AND_BASIS_OF_1

COMPANY OVERVIEW AND BASIS OF PRESENTATION (Policies)	12 Months Ended
COMPANY OVERVIEW AND BASIS OF PRESENTATION (Policies)	Dec. 31, 2013
COMPANY OVERVIEW AND BASIS OF PRESENTATION [Abstract]	'
Basis of Presentation	'
	Basis of Presentation

	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) and include the accounts of ULURU Inc., a Nevada corporation, and its wholly-owned subsidiary, Uluru Delaware Inc., a Delaware corporation. Both companies have a December 31 fiscal year end.

	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ from those estimates and assumptions. These differences are usually minor and are included in our consolidated financial statements as soon as they are known. Our estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from those estimates.

	All intercompany transactions and balances have been eliminated in consolidation.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Cash and Cash Equivalents	'
	Cash and Cash Equivalents

	Cash and cash equivalents include highly liquid investments with original maturities of three months or less. The carrying value of these cash equivalents approximates fair value.

	We invest cash in excess of immediate requirements in money market accounts, certificates of deposit, corporate commercial paper with high quality ratings, and U.S. government securities taking into consideration the need for liquidity and capital preservation. These investments are not held for trading or other speculative purposes.

Accounts Receivable and Allowance for Doubtful Accounts	'
	Accounts Receivable and Allowance for Doubtful Accounts

	Accounts receivable are recorded at the invoiced amount and do not bear interest. We estimate the collectability of our accounts receivable. In order to assess the collectability of these receivables, we monitor the current creditworthiness of each customer and analyze the balances aged beyond the customer's credit terms. Theses evaluations may indicate a situation in which a certain customer cannot meet its financial obligations due to deterioration of its financial viability, credit ratings or bankruptcy. The allowance requirements are based on current facts and are reevaluated and adjusted as additional information is received. Accounts receivable are subject to an allowance for collection when it is probable that the balance will not be collected. As of December 31, 2013 and 2012, the allowance for doubtful accounts was $907 and $18,932, respectively. For the years ended December 31, 2013 and 2012, the accounts written off as uncollectible or previously written off and recovered were $(1,126) and $17,135, respectively.

Inventory	'
	Inventory

	Inventories are stated at the lower of cost or market value. Raw material inventory cost is determined on the first-in, first-out method. Costs of finished goods are determined by an actual cost method. We regularly review inventories on hand and write down the carrying value of our inventories for excess and potentially obsolete inventories based on historical usage and estimated future usage. In assessing the ultimate realization of our inventories, we are required to make judgments as to future demand requirements. As actual future demand or market conditions may vary from those projected by us, adjustment to inventories may be required.

Prepaid Expenses and Deferred Charges	'
	Prepaid Expenses and Deferred Charges

	From time to time fees are payable to the United States Food and Drug Administration (“FDA”) in connection with new drug applications submitted by us and annual prescription drug user fees (“PDUFA”). Such fees are being amortized ratably over the FDA’s prescribed fiscal period of twelve months ending September 30th. As of December 31, 2013 and 2012, the amount of prepaid PDUFA fees was nil and $73,582, respectively.

	Additionally, we amortize our insurance costs ratably over the term of each policy. Typically, our insurance policies are subject to renewal in July and October of each year.

Notes Receivable	'
	Notes Receivable

	Notes receivable are stated at unpaid principle balance. Interest on notes receivable is recognized over the term of the note and is calculated by the simple interest method on principle amounts outstanding. We estimate the collectability of our notes receivable. This estimate is based on similar evaluation criteria as used in estimating the collectability of our trade accounts receivable. Notes receivable are subject to an allowance for collection when it is probable that the balance, or a portion thereof, will not be collected. As of December 31, 2013 and 2012, the allowance for collection for our notes receivable was nil.

Property, Equipment and Leasehold Improvements	'
	Property, Equipment and Leasehold Improvements

	Property, equipment, and leasehold improvements are recorded at cost. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method. Estimated useful lives for property, equipment, and leasehold improvements categories are as follows:

	Furniture, fixtures, and laboratory equipment	7 years
	Computer and office equipment	5 years
	Computer software	3 years
	Leasehold improvements	Lease term
Intangible Assets	'
	Intangible Assets

	We expense internal patent and application costs as incurred because, even though we believe the patents and underlying processes have continuing value, the amount of future benefits to be derived from them are uncertain. Purchased patents are capitalized and amortized over the life of the patent.
Impairment of Assets	'
	Impairment of Assets

	In accordance with the provisions of Accounting Standards Codification (“ASC”) Topic 350-30, Intangibles Other than Goodwill, our policy is to evaluate whether there has been a permanent impairment in the value of long-lived assets and certain identifiable intangibles when certain events have taken place that indicate the remaining unamortized balance may not be recoverable, or at least annually to determine the current value of the intangible asset. When factors indicate that the intangible assets should be evaluated for possible impairment, we use an estimate of undiscounted cash flows. Considerable management judgment is necessary to estimate the undiscounted cash flows. Accordingly, actual results could vary significantly from management’s estimates.

Deferred Financing Costs	'
	Deferred Financing Costs

	We defer financing costs associated with the issuance of our convertible notes payable and amortize those costs over the period of the convertible notes using the effective interest method. In 2012, we incurred $200,000 of financing costs related to our convertible note payable with Inter-Mountain Capital Corp.

	During 2013 and 2012, we recorded amortization of approximately $74,000 and $39,000, respectively, of deferred financing costs. Other assets at December 31, 2013 and 2012 included net deferred financing costs of approximately of $87,000 and $161,000, respectively.

Accrual for Clinical Study Costs	'
	Accrual for Clinical Study Costs

	We record accruals for estimated clinical study costs. Clinical study costs represent costs incurred by clinical research organizations, or CROs, and clinical sites. These costs are recorded as a component of research and development expenses. We analyze the progress of the clinical trials, including levels of patient enrollment and/or patient visits, invoices received and contracted costs when evaluating the adequacy of the accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual costs incurred may or may not match the estimated costs for a given accounting period. As of December 31, 2013 and 2012, the accrual for estimated clinical study costs was nil.

Shipping and Handling Costs	'
	Shipping and Handling Costs

	Shipping and handling costs incurred for product shipments are included in cost of goods sold.

Income Taxes	'
	Income Taxes

	We use the liability method of accounting for income taxes pursuant to ASC Topic 740, Income Taxes. Under this method, deferred income taxes are recorded to reflect the tax consequences in future periods of temporary differences between the tax basis of assets and liabilities and their financial statement amounts at year-end.

Revenue Recognition and Deferred Revenue	'
	Revenue Recognition and Deferred Revenue

	License Fees

	We recognize revenue from license payments not tied to achieving a specific performance milestone ratably during the period over which we are obligated to perform services. The period over which we are obligated to perform services is estimated based on available facts and circumstances. Determination of any alteration of the performance period normally indicated by the terms of such agreements involves judgment on management's part. License revenues with no specific performance criteria are recognized when received from our foreign licensee and their various foreign sub-licensees as there is no control by us over the various foreign sub-licensees and no performance criteria to which we are subject.

	We recognize revenue from performance payments ratably, when such performance is substantially in our control and when we believe that completion of such performance is reasonably probable, over the period during which we estimate that we will complete such performance obligations. In circumstances where the arrangement includes a refund provision, we defer revenue recognition until the refund condition is no longer applicable unless, in our judgment, the refund circumstances are within our operating control and are unlikely to occur.

	Substantive at-risk milestone payments, which are based on achieving a specific performance milestone when performance of such milestone is contingent on performance by others or for which achievement cannot be reasonably estimated or assured, are recognized as revenue when the milestone is achieved and the related payment is due, provided that there is no substantial future service obligation associated with the milestone.

	Royalty Income

	We receive royalty revenues under license agreements with a number of third parties that sell products based on technology we have developed or to which we have rights. The license agreements provide for the payment of royalties to us based on sales of the licensed products. We record these revenues based on estimates of the sales that occurred during the relevant period. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties we have been paid (adjusted for any changes in facts and circumstances, as appropriate).

	We maintain regular communication with our licensees in order to gauge the reasonableness of our estimates. Differences between actual royalty revenues and estimated royalty revenues are reconciled and adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material based on actual amounts paid by licensees. As it relates to royalty income, there are no future performance obligations on our part under these license agreements. To the extent we do not have sufficient ability to accurately estimate revenue; we record it on a cash basis.

	Product Sales

	We recognize revenue and related costs from the sale of our products at the time the products are shipped to the customer. Provisions for returns, rebates, and discounts are established in the same period the related product sales are recorded.

	We review the supply levels of our products sold to major wholesalers in the U.S., primarily by reviewing reports supplied by our major wholesalers and available volume information for our products, or alternative approaches. When we believe wholesaler purchasing patterns have caused an unusual increase or decrease in the sales of a major product compared with underlying demand, we disclose this in our product sales discussion if we believe the amount is material to the product sales trend; however, we are not always able to accurately quantify the amount of stocking or destocking. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.

	We establish sales return accruals for anticipated product returns. We record the return amounts as a deduction to arrive at our net product sales. Consistent with Revenue Recognition accounting guidance, we estimate a reserve when the sales occur for future product returns related to those sales. This estimate is primarily based on historical return rates as well as specifically identified anticipated returns due to known business conditions and product expiry dates. Actual product returns have been nil over the past two years.

	We establish sales rebate and discount accruals in the same period as the related sales. The rebate and discount amounts are recorded as a deduction to arrive at our net product sales. We base these accruals primarily upon our historical rebate and discount payments made to our customer segment groups and the provisions of current rebate and discount contracts.

	Sponsored Research Income

	Sponsored research income has no significant associated costs since it is being paid only for information pertaining to a specific research and development project in which the sponsor may become interested in acquiring products developed thereby. Payments received prior to our performance are deferred. Contract amounts are not recognized as revenue until the customer accepts or verifies the research has been completed.
Research and Development Expenses	'
	Research and Development Expenses

	Pursuant to ASC Topic 730, Research and Development, our research and development costs are expensed as incurred.

	Research and development expenses include, but are not limited to, salaries and benefits, laboratory supplies, facilities expenses, preclinical development cost, clinical trial and related clinical manufacturing expenses, contract services, consulting fees and other outside expenses. The cost of materials and equipment or facilities that are acquired for research and development activities and that have alternative future uses are capitalized when acquired. There were no such capitalized materials, equipment or facilities for the years ended December 31, 2013 and 2012.

	We may enter into certain research agreements in which we share expenses with a collaborator. We may also enter into other collaborations where we are reimbursed for work performed on behalf of our collaborative partners. We record the expenses for such work as research and development expenses. If the arrangement is a cost-sharing arrangement and there is a period during which we receive payments from the collaborator, we record payments by the collaborator for their share of the development effort as a reduction of research and development expense. If the arrangement is a reimbursement of research and development expenses, we record the reimbursement as sponsored research income.

Basic and Diluted Net Loss Per Common Share	'
	Basic and Diluted Net Loss Per Common Share

	In accordance with ASC Topic 260, Earnings per Share, basic earnings (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period increased to include potential dilutive common shares. The effect of outstanding stock options, restricted vesting common stock and warrants, when dilutive, is reflected in diluted earnings (loss) per common share by application of the treasury stock method. We have excluded all outstanding stock options, restricted vesting common stock and warrants from the calculation of diluted net loss per common share because all such securities are antidilutive for all periods presented.

Concentrations of Credit Risk	'
	Concentrations of Credit Risk

	Concentration of credit risk with respect to financial instruments, consisting primarily of cash and cash equivalents, that potentially expose us to concentrations of credit risk due to the use of a limited number of banking institutions and due to maintaining cash balances in banks, which, at times, may exceed the limits of amounts insured by the Federal Deposit Insurance Corporation. During 2013, we utilized Bank of America, N.A. as our banking institution. At December 31, 2013 and December 31, 2012 our cash and cash equivalents totaled $5,119 and $21,549, respectively. We also invest cash in excess of immediate requirements in money market accounts, certificates of deposit, corporate commercial paper with high quality ratings, and U.S. government securities. These investments are not held for trading or other speculative purposes. We are exposed to credit risk in the event of default by these high quality corporations.

	Concentration of credit risk with respect to trade accounts receivable are customers with balances that exceed 5% of total consolidated trade accounts receivable at December 31, 2013 and at December 31, 2012. As of December 31, 2013, two customers exceeded the 5% threshold, with 86% and 11%, respectively. Two customers exceeded the 5% threshold at December 31, 2012, with 77% and 13%, respectively. To reduce risk, we routinely assess the financial strength of our most significant customers and monitor the amounts owed to us, taking appropriate action when necessary. As a result, we believe that accounts receivable credit risk exposure is limited. We maintain an allowance for doubtful accounts, but historically have not experienced any significant losses related to an individual customer or group of customers.

Concentrations of Foreign Currency Risk	'
	Concentrations of Foreign Currency Risk

	Substantially all of our revenue and expenses are denominated in U.S. dollars, although we expect our revenues in international territories to increase in the future. Certain of our licensing and distribution agreements in international territories are denominated in Euros. Currently, we do not employ forward contracts or other financial instruments to mitigate foreign currency risk. As our international operations grow, we may engage in hedging activities to hedge our exposure to foreign currency risk.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments

	In accordance with portions of ASC Topic 820, Fair Value Measurements, certain assets and liabilities of the Company are required to be recorded at fair value. Fair value is determined based on the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants.

	Our financial instruments, including cash, cash equivalents, accounts receivable, and accounts payable are carried at cost, which approximates their fair value because of the short-term maturity of these instruments. We believe that the carrying value of our other receivable, notes receivable and accrued interest, and convertible note payable balances approximates fair value based on a valuation methodology using the income approach and a discounted cash flow model.

Derivatives	'
	Derivatives

	We occasionally issue financial instruments that contain an embedded instrument. At inception, we assess whether the economic characteristics of the embedded derivative instrument are clearly and closely related to the economic characteristics of the financial instrument (host contract), whether the financial instrument that embodies both the embedded derivative instrument and the host contract is currently measured at fair value with changes in fair value reported in earnings, and whether a separate instrument with the same terms as the embedded instrument would meet the definition of a derivative instrument.

	If the embedded derivative instrument is determined not to be clearly and closely related to the host contract, is not currently measured at fair value with changes in fair value reported in earnings, and the embedded derivative instrument would qualify as a derivative instrument, the embedded derivative instrument is recorded apart from the host contract and carried at fair value with changes recorded in current-period earnings.

	We determined that all embedded items associated with financial instruments during 2013 and 2012 which qualify for derivative treatment, were properly separated from their host. As of December 31, 2013 and 2012, we did not have any derivative instruments.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Estimated useful lives for property and equipment	'
	Property, equipment, and leasehold improvements are recorded at cost. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method. Estimated useful lives for property, equipment, and leasehold improvements categories are as follows:

	Furniture, fixtures, and laboratory equipment	7 years
	Computer and office equipment	5 years
	Computer software	3 years
	Leasehold improvements	Lease term

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	12 Months Ended
SEGMENT INFORMATION (Tables)	Dec. 31, 2013
SEGMENT INFORMATION [Abstract]	'
Revenues per geographic area	'
	Revenues per geographic area, along with relative percentages of total revenues, for the year ended December 31, are summarized as follows:

	Revenues		2013				%				2012		%
	Domestic		$	65,546				18	%		$	177,440		48	%
	International			305,022				82	%			193,154		52	%
	Total		$	370,568				100	%		$	370,594		100	%
Customers with greater than 10% of total sales	'
	A significant portion of our revenues are derived from a few major customers. Customers with greater than 10% of total revenues, along with their relative percentage of total revenues, for the year ended December 31 are represented on the following table:

	Customers	Product		2013				2012
	Customer A	Altrazeal®			67	%			32	%
	Customer B	Altrazeal® Veterinary			-				14	%
	Customer C	Aphthasol®			-				13	%
	Total				67	%			59	%

INVENTORY_Tables

INVENTORY (Tables)	12 Months Ended
INVENTORY (Tables)	Dec. 31, 2013
INVENTORY [Abstract]	'
Inventory	'
	The components of inventory, at the different stages of production, consisted of the following at December 31:

	Inventory	2013		2012
	Finished goods	$	85,993	$	303,779
	Work-in-progress		299,464		190,794
	Raw materials		10,148		33,070
	Total	$	395,605	$	527,643

PROPERTY_EQUIPMENT_and_LEASEHO1

PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS (Tables)	12 Months Ended
PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS (Tables)	Dec. 31, 2013
PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS [Abstract]	'
Property, equipment and leasehold improvements	'
	Property, equipment and leasehold improvements, net, consisted of the following at December 31:

	Property, equipment and leasehold improvements	2013			2012
	Laboratory equipment	$	424,888		$	424,888
	Manufacturing equipment		1,581,728			1,547,572
	Computers, office equipment, and furniture		140,360			140,360
	Computer software		4,108			4,108
	Leasehold improvements		95,841			95,841
			2,246,925			2,212,769
	Less: accumulated depreciation and amortization		(1,608,311	)		(1,367,234	)
	Property, equipment and leasehold improvements, net	$	638,614		$	845,535

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	12 Months Ended
INTANGIBLE ASSETS (Tables)	Dec. 31, 2013
INTANGIBLE ASSETS [Abstract]	'
Intangible assets	'
	Intangible assets are comprised of patents acquired in October 2005. Intangible assets, net consisted of the following at December 31:

	Intangible assets	2013			2012
	Patent - Amlexanox (Aphthasol®)	$	2,090,000		$	2,090,000
	Patent - Amlexanox (OraDisc™ A)		6,873,080			6,873,080
	Patent - OraDisc™		73,000			73,000
	Patent - Hydrogel nanoparticle aggregate		589,858			589,858
			9,625,938			9,625,938
	Less: accumulated amortization		(5,955,101	)		(5,479,953	)
	Intangible assets, net	$	3,670,837		$	4,145,985
Future aggregate amortization expense for intangible assets	'
	Amortization expense for intangible assets was $475,148 and $476,450 for the years ended December 31, 2013 and 2012, respectively. The future aggregate amortization expense for intangible assets, remaining as of December 31, 2013, is as follows:

	Calendar Years	Future Amortization
	Calendar Years	Expense
	2014	$	475,148
	2015		475,148
	2016		476,450
	2017		475,148
	2018		475,148
	2019 & Beyond		1,293,795
	Total	$	3,670,837

INVESTMENT_IN_UNCONSOLIDATED_S1

INVESTMENT IN UNCONSOLIDATED SUBSIDIARY (Tables)	12 Months Ended
INVESTMENT IN UNCONSOLIDATED SUBSIDIARY (Tables)	Dec. 31, 2013
INVESTMENT IN UNCONSOLIDATED SUBSIDIARY [Abstract]	'
Summarized financial information for investment	'
	Summarized financial information for our investment in Altrazeal Trading Ltd. assuming 100% ownership is as follows:

	Altrazeal Trading Ltd.	2012
	Balance sheet
	Total assets	$	415,248
	Total liabilities	$	205,991
	Total stockholders’ equity	$	209,257
	Statement of operations
	Revenues	$	131,869
	Net (loss)	$	(330,961	)

ACCRUED_LIABILITIES_Tables

ACCRUED LIABILITIES (Tables)	12 Months Ended
ACCRUED LIABILITIES (Tables)	Dec. 31, 2013
ACCRUED LIABILITIES [Abstract]	'
Accrued liabilities	'
	Accrued liabilities consisted of the following at December 31:

	Accrued Liabilities	2013		2012
	Accrued taxes – payroll	$	106,299	$	106,299
	Accrued compensation/benefits		148,683		213,005
	Accrued insurance payable		60,113		52,629
	Product rebates/returns		32		81
	Other		836		951
	Total accrued liabilities	$	315,963	$	372,965

CONVERTIBLE_DEBT_Tables

CONVERTIBLE DEBT (Tables)	12 Months Ended
CONVERTIBLE DEBT (Tables)	Dec. 31, 2013
CONVERTIBLE DEBT [Abstract]	'
Information relating to convertible notes payable	'
	Information relating to our convertible notes payable is as follows:

													As of December 31, 2013
	Transaction		Initial		Interest			Maturity		Conversion			Principal			Unamortized			Carrying
			Principal		Rate			Date		Price (1)(2)			Balance			Debt			Value
			Amount													Discount
	June 2011 Note		$	140,000		10	%	6/13/14		$	1.2		$	140,000		$	1,780		$	138,220
	July 2011 Note			125,000		10	%	7/28/14		$	1.08			125,000			4,262			120,738
	June 2012 Note			2,210,000		8	%	3/27/15		$	0.35			1,093,638			205,539			888,099
	Total		$	2,475,000									$	1,358,638		$	211,581		$	1,147,057

	-1	The outstanding principal balance of the June 2011 Note and the July 2011 Note may be converted, at the option of Mr. Gray, into shares of common stock at a fixed conversion price of $1.20 per share and $1.08 per shares, respectively.
	-2	The outstanding principal balance of the June 2012 Note may be converted, at the option of Inter-Mountain, into shares of common stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations.
Schedule of future minimum payments relating to our convertible notes payable	'
	The future minimum payments relating to our convertible notes payable, as of December 31, 2013, are as follows:

			Payments Due By Period
	Transaction		Total		2014				2015			2016			2017			2018
	June 2011 Note		$	140,000	$	140,000			$	-		$	-		$	-		$	-
	July 2011 Note			125,000		125,000				-			-			-			-
	June 2012 Note			1,093,638		1,093,638				-			-			-			-
	Total		$	1,358,638	$	1,358,638			$	-		$	-		$	-		$	-

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
STOCKHOLDERS' EQUITY (Tables)	Dec. 31, 2013
STOCKHOLDERS' EQUITY [Abstract]	'
Warrants outstanding and number of shares of common stock subject to exercise	'
	The following table summarizes the warrants outstanding and the number of shares of common stock subject to exercise as of December 31, 2013 and the changes therein during the two years then ended:

			Number of Shares of Common Stock Subject to Exercise			Weighted – Average
			Number of Shares of Common Stock Subject to Exercise			Exercise Price
	Balance as of December 31, 2011			612,594		$	2.45

	Warrants issued			1,428,571			0.35
	Warrants exercised			-			-
	Warrants cancelled			-			-
	Balance as of December 31, 2012			2,041,165		$	0.98

	Warrants issued			4,445,714			0.56
	Warrants exercised (1)			(1,571,428	)		0.35
	Warrants cancelled			(250,000	)		0.35
	Balance as of December 31, 2013 (1)			4,665,451		$	0.82

	-1	As part of the June 2012 Note, Inter-Mountain received a total of seven warrants to purchase, if they all vest, an aggregate of 3,142,857 shares of common stock, which number of shares could increase based upon the terms and conditions of the warrants. The warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017. Warrants for 785,714, 392,857, 392,857, and 392,857 shares of common stock vested on June 27, 2012, December 31, 2012, February 26, 2013, and July 15, 2013, respectively, and three warrants for 1,571,428 shares of common stock have been exercised. For the purposes of this Table, only such net vested shares of common stock from the fourth warrant (392,857 shares) have been included, based upon an exercise price of $0.35 per share of common stock. On January 22, 2014, we elected to offset and deduct the three remaining Investor Notes from the principle amount due to Inter-Mountain under the June 2012 Note and as a result of the offset and deduction the three remaining warrants terminated.
Expiration dates for warrants subject to exercise	'
	Of the warrant shares subject to exercise as of December 31, 2013, expiration of the right to exercise is as follows:

	Date of Expiration		Number of Warrant Shares of Common Stock Subject to Expiration
	3-Jan-14			3,000,000
	23-Jul-14			69,050
	15-May-15			357,155
	13-Jun-16			35,000
	16-Jul-16			116,667
	28-Jul-16			34,722
	27-Jun-17			392,857
	14-Mar-18			660,000
	Total			4,665,451

EARNINGS_PER_SHARE_Tables

EARNINGS PER SHARE (Tables)	12 Months Ended
EARNINGS PER SHARE (Tables)	Dec. 31, 2013
EARNINGS PER SHARE [Abstract]	'
Common shares excluded from calculating basic and diluted net loss per common share	'
	Shares used in calculating basic and diluted net loss per common share exclude these potential common shares as of December 31:

			31-Dec-13		31-Dec-12
	Warrants to purchase common stock (1)			4,665,451		2,041,165
	Stock options to purchase common stock			1,014,907		158,409
	Unvested restricted common stock			-		300
	Common stock issuable upon the assumed conversion of our convertible note payable from June 2012 (2)			3,124,680		5,617,974
	Common stock issuable upon the assumed conversion of our convertible notes payable from June 2011 and July 2011 (3)			253,315		368,637
	Common stock issuable upon the assumed conversion of our Series A preferred stock (4)(5)			-		1,002,634
	Total			9,058,353		9,189,119

	-1	As part of the June 2012 Note, Inter-Mountain received a total of seven warrants to purchase, if they all vest, an aggregate of 3,142,857 shares of common stock, which number of shares could increase based upon the terms and conditions of the warrants. The warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017. Warrants for 785,714, 392,857, 392,857, and 392,857 shares of common stock vested on June 27, 2012, December 31, 2012, February 26, 2013, and July 15, 2013, respectively, and three warrants for 1,571,428 shares of common stock have been exercised. For the purposes of this Table, only such net vested shares of common stock from the fourth warrant (392,857 shares) have been included, based upon an exercise price of $0.35 per share of common stock. On January 22, 2014, we elected to offset and deduct the three remaining Investor Notes from the principle amount due to Inter-Mountain under the June 2012 Note and as a result of the offset and deduction the three remaining warrants terminated.
	-2	The outstanding principal balance and the accrued and unpaid interest of the June 2012 Note may be converted, at the option of Inter-Mountain, into shares of common stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations. For the purposes of this Table, we have assumed a conversion price of $0.35 per share and no ownership limitations.
	-3	The outstanding principal balance of the June 2011 Note and the July 2011 Note may be converted, at the option of Mr. Gray, into shares of common stock at a fixed conversion price of $1.20 per share and $1.08 per share, respectively. The accrued and unpaid interest for each convertible note payable may be converted, at the option of Mr. Gray, into shares of common stock at a conversion price based upon the average of the five trading days prior to the payment date, which for the purposes of this Table we have assumed to be December 31, 2013.
	-4	The outstanding Series A preferred stock and the accrued and unpaid dividends thereon are convertible into shares of the Company’s common stock at the Company’s option at any time after six-months from the date of issuance of the Series A preferred stock. The conversion price for the holder is fixed at $0.70 per share with no adjustment mechanisms, resets, ratchets, or anti-dilution covenants other than the customary adjustments for stock splits. For the purposes of this Table, we have assumed a conversion price of $0.70 per share.
	-5	On August 15, 2013, we provided notice to Ironridge for the redemption of all of our Series A Shares held by Ironridge, a total of 65 Series A Shares. An affiliate of Ironridge, the issuer of promissory notes held by us, due 7.5 years from the issue date, in the principal amount of $969,000, agreed to accept the cancellation of the promissory notes held by us as full and final payment for the redemption amounts of the Series A Shares.

SHARE_BASED_COMPENSATION_Table

SHARE BASED COMPENSATION (Tables)	12 Months Ended
SHARE BASED COMPENSATION (Tables)	Dec. 31, 2013
SHARE BASED COMPENSATION [Abstract]	'
Stock option awards granted	'
	Our Board of Directors granted the following incentive stock option awards to executives or employees and nonstatutory stock option awards to directors or non-employees for the years ended December 31:

			2013				2012(1)
	Incentive Stock Options
	Quantity			232,500				-
	Weighted average fair value per share		$	0.24				-
	Fair value		$	56,112				-

	Nonstatutory Stock Options
	Quantity			735,000				-
	Weighted average fair value per share		$	0.24				-
	Fair value		$	177,388				-

	-1	The Company did not award any share-based compensation for the year ended December 31, 2012.
Weighted average assumptions to estimate the fair value of share based awards	'
	We account for share-based compensation under ASC Topic 718, Stock Compensation, which requires the measurement and recognition of compensation expense in the financial statements for all share-based payment awards made to employees, consultants, and directors is measured based on the estimated fair value of the award on the grant date. We use the Black-Scholes option-pricing model to estimate the fair value of share-based awards with the following weighted average assumptions for the years ended December 31:

			2013				2012 (4)
	Incentive Stock Options
	Expected volatility (1)			103.55	%			-
	Risk-fee interest rate % (2)			0.81	%			-
	Expected term (in years)			5				-
	Dividend yield (3)			-				-
				-
	Nonstatutory Stock Options
	Expected volatility (1)			103.55	%			-
	Risk-fee interest rate % (2)			0.81	%			-
	Expected term (in years)			5				-
	Dividend yield (3)			-				-

	-1	Expected volatility assumption was based upon a combination of historical stock price volatility measured on a daily basis and an estimate of expected future stock price volatility.
	-2	Risk-free interest rate assumption is based upon U.S. Treasury bond interest rates appropriate for the term of the stock options.
	-3	The Company does not currently intend to pay cash dividends, thus has assumed a 0% dividend yield.
	-4	The Company did not award any share-based compensation for the year ended December 31, 2012.
Allocated share-based compensation expense	'
	The following table summarizes share-based compensation related to stock options for the years ended December 31:

			2013				2012
	Research and development		$	16,863			$	6,280
	Selling, general and administrative			64,076				31,617
	Total share-based compensation expense		$	80,939			$	37,897
Stock option activity	'
	The following table summarizes the stock options outstanding and the number of shares of common stock subject to exercise as of December 31, 2013 and the changes therein during the two years then ended:

			Stock Options				Weighted Average Exercise Price per Share
	Outstanding as of December 31, 2011			287,745			$	16.89
	Granted			-				-
	Forfeited/cancelled			(129,336	)			22.49
	Exercised			-				-
	Outstanding as of December 31, 2012			158,409				12.32
	Granted			967,500				0.33
	Forfeited/cancelled			(111,002	)			1.03
	Exercised			-				-
	Outstanding as of December 31, 2013			1,014,907			$	2.12
Stock option grants outstanding and exercisable	'
	The following table presents the stock option grants outstanding and exercisable as of December 31, 2013:

	Options Outstanding										Options Exercisable
	Stock Options Outstanding				Weighted Average Exercise Price per Share				Weighted Average Remaining Contractual Life in Years		Stock		Weighted Average Exercise Price per Share
											Options
											Exercisable
		892,500			$	0.33				9.2		197,500	$	0.33
		53,334				2.38				4.5		46,668		2.36
		30,002				14.4				3.3		30,002		14.4
		39,071				33.35				3.8		39,071		33.35
		1,014,907			$	2.12				8.6		313,241	$	6.1
Nonvested restricted stock awards	'
	The following table summarizes share-based compensation related to restricted stock awards for the years ended December 31:

			2013				2012
	Research and development		$	444			$	3,762
	Selling, general and administrative			547				4,535
	Total share-based compensation expense		$	991			$	8,297

	At December 31, 2013, the balance of unearned share-based compensation to be expensed in future periods related to restricted stock awards, as adjusted for expected forfeitures, is nil.

	The following table summarizes the non-vested restricted stock awards outstanding and the number of shares of common stock subject to potential issue as of December 31, 2013 and the changes therein during the two years then ended:

			Restricted Stock				Weighted Average Grant Date Fair Value
	Outstanding as of December 31, 2011			1,096			$	41.47
	Granted			-				-
	Forfeited/cancelled			(97	)			34.59
	Exercised/issued			(699	)			45.39
	Outstanding as of December 31, 2012			300			$	34.59
	Granted			-				-
	Forfeited/cancelled			-				-
	Exercised/issued			(300	)			34.59
	Outstanding as of December 31, 2013			-			$	-

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Dec. 31, 2013
FAIR VALUE MEASUREMENTS [Abstract]	'
Fair value of our financial instruments	'
	The fair value of our financial instruments consisted of the following at December 31:

	Description	2013		2012
	Assets:
	Notes receivable and accrued interest	$	777,710	$	1,302,220

	Liabilities:
	Convertible note – June 2011	$	138,220	$	134,154
	Convertible note – July 2011	$	120,738	$	113,084
	Convertible note – June 2012	$	888,099	$	1,593,924

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
INCOME TAXES (Tables)	Dec. 31, 2013
INCOME TAXES [Abstract]	'
Expiration of consolidated operating loss carryforwards and research credit carryforwards	'
	NOTE 19.	INCOME TAXES

	There was no current federal tax provision or benefit recorded for any period since inception, nor were there any recorded deferred income tax assets, as such amounts were completely offset by valuation allowances. Deferred tax assets as of December 31, 2013, of $18,344,933 were reduced to zero, after considering the valuation allowance of $18,344,933, since there is no assurance of future taxable income. As of December 31, 2013 we have consolidated net operating loss carryforwards (“NOL”) and research credit carryforwards for income tax purposes of approximately $49,550,149 and $511,949, respectively.

	The following are the consolidated operating loss carryforwards and research credit carryforwards that will begin expiring as follows:

	Calendar Years		Consolidated Operating Loss Carryforwards			Research Activities
	Calendar Years		Consolidated Operating Loss Carryforwards			Carryforwards
	2021		$	34,248		$	-
	2023			95,666			-
	2024			910,800			13,584
	2025			1,687,528			21,563
	2026			11,950,281			60,797
	2027			3,431,365			85,052
	2028			8,824,940			139,753
	2029			6,889,761			81,940
	2030			5,113,583			41,096
	2031			3,728,626			43,592
	2032			3,695,792			8,690
	2033			3,187,559			15,882
	Total		$	49,550,149		$	511,949
Deferred tax assets and deferred tax liabilities	'
	An analysis of the tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2013 and 2012 are as follows:

			2013			2012
	Deferred tax assets:
	Net operating loss carryforwards		$	17,657,746		$	16,549,134
	Intangible assets			247,248			305,552
	Other			512,286			502,732
	Total gross deferred tax assets			18,417,280			17,357,418

	Deferred tax liabilities:
	Property and equipment			72,347			77,839
	Total gross deferred tax liabilities			72,347			77,839

	Net total of deferred assets and liabilities			18,344,933			17,279,579
	Valuation allowance			(18,344,933	)		(17,279,579	)
	Net deferred tax assets		$	---		$	---
Reconciliation of expected statutory federal income tax rate to actual income tax rate	'
	The following is a reconciliation of the expected statutory federal income tax rate to our actual income tax rate for the years ended December 31:

			2013			2012
	Expected income tax (benefit) at federal statutory tax rate -35%		$	( 1,137,320	)	$	( 1,309,975	)

	Permanent differences			21,754			16,500
	Research tax credits			(15,882	)		(8,690	)
	Amortization of deferred start up costs			-			-
	Valuation allowance			1,131,448			1,302,165
	Income tax expense		$	-		$	-

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
COMMITMENTS AND CONTINGENCIES (Tables)	Dec. 31, 2013
COMMITMENTS AND CONTINGENCIES [Abstract]	'
Future minimum lease payments	'
	The future minimum lease payments under the 2013 office lease and the 2010 equipment lease are as follows as of December 31, 2013:

	Calendar Years		Future Lease Expense
	2014		$	120,917
	2015			28,881
	2016			-
	2017			-
	2018			-
	Total		$	149,798
Summary of compensation earned, compensation paid in cash, and compensation temporarily deferred	'
	As of December 31, 2013, the following table summarizes the compensation temporarily deferred since 2011:

	Name		2013			2012		2011		Total
	Kerry P. Gray (1)		$	(91,000	)	$	220,673	$	140,313	$	269,986
	Terrance K. Wallberg			(35,769	)	$	24,230	$	36,539	$	25,000
	Key executives			(20,000	)	$	27,253	$	20,986	$	28,239
	Total		$	(146,739	)	$	272,156	$	197,838	$	323,225

		-1	During 2013, Mr. Gray temporarily deferred compensation of $221,500 which consisted of $11,500 earned pursuant to a Separation Agreement and $210,000 for his duties as Chairman of the Executive Committee of the Company’s Board of Directors. During 2013, Mr. Gray was also repaid $312,500 of temporarily deferred compensation, of which $300,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.

SELECTED_QUARTERLY_FINANCIAL_D1

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)	12 Months Ended
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)	Dec. 31, 2013
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) [Abstract]	'
Quarterly financial information	'
	The following table contains condensed information from the Company’s Consolidated Statements of Operations for each quarter of the years ended December 31, 2013 and 2012. We have derived this data from its unaudited quarterly financial statements. We believe that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.

		First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	2013
	Revenues	$	102,044		$	28,884		$	110,580		$	129,060
	Costs and expenses		649,413			744,932			743,033			880,888
	Operating (loss)		(547,369	)		(716,048	)		(632,453	)		(751,828	)
	Other income (expense)		(109,221	)		(106,737	)		(110,816	)		(106,442	)
	Net (loss)	$	(656,590	)	$	(822,785	)	$	(743,269	)	$	(858,270	)
	Less preferred stock dividends		(12,021	)		(12,154	)		(6,061	)		---
	Net (loss) allocable to common stockholders	$	(668,611	)	$	(834,939	)	$	(749,330	)	$	(858,270	)

	Basic and diluted net (loss) per common share	$	(0.06	)	$	(0.06	)	$	(0.05	)	$	(0.04	)

	2012
	Revenues	$	60,005		$	56,211		$	88,922		$	165,456
	Costs and expenses		879,717			884,289			837,149			1,034,259
	Operating (loss)		(819,712	)		(828,078	)		(748,227	)		(868,803	)
	Other income (expense)		(23,697	)		(30,068	)		(103,498	)		(109,266	)
	Net (loss)	$	(843,409	)	$	(858,146	)	$	(851,725	)	$	(978,069	)
	Less preferred stock dividends		(10,726	)		(12,154	)		(12,288	)		(12,288	)
	Net (loss) allocable to common stockholders	$	(854,135	)	$	(870,300	)	$	(864,013	)	$	(990,357	)

	Basic and diluted net (loss) per common share	$	(0.11	)	$	(0.11	)	$	(0.10	)	$	(0.10	)

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Customer	Customer	Dec. 31, 2011
Trade Accounts Receivable and Allowance for Doubtful Accounts [Abstract]	'	'	'
Allowance for doubtful accounts	$907	$18,932	'
Accounts written off as uncollectible	-1,126	17,135	'
Prepaid Expenses and Deferred Charges [Abstract]	'	'	'
Prepaid PDUFA fees	0	73,582	'
Deferred Financing Costs [Abstract]	'	'	'
Financing costs related to convertible notes payable	'	200,000	'
Amortization costs	74,000	39,230	'
Deferred financing cost included in other assets	87,000	161,000	'
Product Sales [Abstract]	'	'	'
Period over which no actual product returns occurred	'2 years	'	'
Concentrations of Credit Risk [Abstract]	'	'	'
Cash and cash equivalents	$5,119	$21,549	$46,620
Concentration Risk [Line Items]	'	'	'
Minimum threshold limit of trade accounts receivable (in hundredths)	5.00%	5.00%	'
Number of customers exceeds threshold limit of 5%	2	2	'
Concentration risk percentage (in hundredths)	67.00%	59.00%	'
Accounts Receivable [Member] \| Customer One [Member] \| Credit Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration risk percentage (in hundredths)	86.00%	77.00%	'
Accounts Receivable [Member] \| Customer Two [Member] \| Credit Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration risk percentage (in hundredths)	11.00%	13.00%	'
Furniture, Fixtures, and Laboratory Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Estimated useful life of property and equipment	'7 years	'	'
Computer and Office Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Estimated useful life of property and equipment	'5 years	'	'
Computer Software [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Estimated useful life of property and equipment	'3 years	'	'
Leasehold Improvements [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Estimated useful life of property and equipment, description	'Lease term	'	'

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
									Segment
									Licensee
SEGMENT INFORMATION [Abstract]	'	'	'	'	'	'	'	'	'	'
Number of business segments	'	'	'	'	'	'	'	'	1	'
Number of international licensees	'	'	'	'	'	'	'	'	7	'
Revenues per geographic area [Abstract]	'	'	'	'	'	'	'	'	'	'
Total Revenues	$129,060	$110,580	$28,884	$102,044	$165,456	$88,922	$56,211	$60,005	$370,568	$370,594
Total revenue, percentage (in hundredths)	'	'	'	'	'	'	'	'	100.00%	100.00%
Revenue, Major Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Sales from major customer, percentage (in hundredths)	'	'	'	'	'	'	'	'	67.00%	59.00%
Customer A [Member] \| Altrazeal [Member]	'	'	'	'	'	'	'	'	'	'
Revenue, Major Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Sales from major customer, percentage (in hundredths)	'	'	'	'	'	'	'	'	67.00%	32.00%
Customer B [Member] \| Altrazeal Veterinary [Member]	'	'	'	'	'	'	'	'	'	'
Revenue, Major Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Sales from major customer, percentage (in hundredths)	'	'	'	'	'	'	'	'	0.00%	14.00%
Customer C [Member] \| Aphthasol [Member]	'	'	'	'	'	'	'	'	'	'
Revenue, Major Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Sales from major customer, percentage (in hundredths)	'	'	'	'	'	'	'	'	0.00%	13.00%
Domestic [Member]	'	'	'	'	'	'	'	'	'	'
Revenues per geographic area [Abstract]	'	'	'	'	'	'	'	'	'	'
Total Revenues	'	'	'	'	'	'	'	'	65,546	177,440
Total revenue, percentage (in hundredths)	'	'	'	'	'	'	'	'	18.00%	48.00%
International [Member]	'	'	'	'	'	'	'	'	'	'
Revenues per geographic area [Abstract]	'	'	'	'	'	'	'	'	'	'
Total Revenues	'	'	'	'	'	'	'	'	$305,022	$193,154
Total revenue, percentage (in hundredths)	'	'	'	'	'	'	'	'	82.00%	52.00%

OTHER_RECEIVABLE_Details

OTHER RECEIVABLE (Details) (USD $)	12 Months Ended
OTHER RECEIVABLE (Details) (USD $)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2013
OTHER RECEIVABLE [Abstract]	'	'	'	'
License receivable, maximum	'	'	'	$5,100,000
Guaranteed license receivable	1,050,000	'	'	'
Guaranteed payments received	250,000	250,000	550,000	'
Early remittance of final guaranteed payment	$220,000	'	'	'

NOTES_RECEIVABLE_Details

NOTES RECEIVABLE (Details) (USD $)	0 Months Ended			12 Months Ended
	Dec. 31, 2012	Nov. 30, 2012	Oct. 05, 2012	Dec. 31, 2013	Dec. 31, 2012
				PromissoryNote	PromissoryNote
				InvestorNote
Information relating to convertible notes payable [Abstract]	'	'	'	'	'
Initial Principal Amount	'	'	'	$2,475,000	'
Purchase price paid in the form of promissory notes	'	'	'	0	1,500,000
June 2012 Note [Member]	'	'	'	'	'
Information relating to convertible notes payable [Abstract]	'	'	'	'	'
Initial Principal Amount	'	'	'	2,210,000	'
Secured convertible note [Member] \| June 2012 Note [Member]	'	'	'	'	'
Information relating to convertible notes payable [Abstract]	'	'	'	'	'
Purchase price paid in the form of promissory notes	'	'	'	1,500,000	1,500,000
Number of promissory notes issued under purchase agreement	'	'	'	6	6
Principal amount of promissory notes	250,000	'	'	250,000	250,000
Payment received	50,000	100,000	100,000	'	'
Notes receivable and accrued interest	'	'	'	777,710	'
Notes receivable	'	'	'	687,500	'
Accrued interest	'	'	'	$90,210	'
Number of Investor Notes	'	'	'	3	'

INVENTORY_Details

INVENTORY (Details) (USD $)	12 Months Ended
INVENTORY (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
INVENTORY [Abstract]	'	'
Obsolete finished goods	$60,000	$88,000
Components of inventory [Abstract]	'	'
Finished goods	85,993	303,779
Work-in-progress	299,464	190,794
Raw materials	10,148	33,070
Total	$395,605	$527,643

PROPERTY_EQUIPMENT_and_LEASEHO2

PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, equipment and leasehold improvements, net [Abstract]	'	'
Property, equipment and leasehold improvements, gross	$2,246,925	$2,212,769
Less: accumulated depreciation and amortization	-1,608,311	-1,367,234
Property, equipment and leasehold improvements, net	638,614	845,535
Depreciation expense	244,704	291,274
Laboratory Equipment [Member]	'	'
Property, equipment and leasehold improvements, net [Abstract]	'	'
Property, equipment and leasehold improvements, gross	424,888	424,888
Manufacturing Equipment [Member]	'	'
Property, equipment and leasehold improvements, net [Abstract]	'	'
Property, equipment and leasehold improvements, gross	1,581,728	1,547,572
Computers, Office Equipment, and Furniture [Member]	'	'
Property, equipment and leasehold improvements, net [Abstract]	'	'
Property, equipment and leasehold improvements, gross	140,360	140,360
Computer Software [Member]	'	'
Property, equipment and leasehold improvements, net [Abstract]	'	'
Property, equipment and leasehold improvements, gross	4,108	4,108
Leasehold Improvements [Member]	'	'
Property, equipment and leasehold improvements, net [Abstract]	'	'
Property, equipment and leasehold improvements, gross	$95,841	$95,841

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	12 Months Ended
INTANGIBLE ASSETS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, gross	$9,625,938	$9,625,938
Less: accumulated amortization	-5,955,101	-5,479,953
Intangible assets, net	3,670,837	4,145,985
Amortization expense	475,148	476,450
Future aggregate amortization expense for intangible assets [Abstract]	'	'
2014	475,148	'
2015	475,148	'
2016	476,450	'
2017	475,148	'
2018	475,148	'
2019 & Beyond	1,293,795	'
Total	3,670,837	'
Patents [Member] \| Amlexanox (Aphthasol) [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, gross	2,090,000	2,090,000
Patents [Member] \| Amlexanox (OraDiscA) [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, gross	6,873,080	6,873,080
Patents [Member] \| OraDisc [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, gross	73,000	73,000
Patents [Member] \| Hydrogel Nanoparticle Aggregate [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, gross	$589,858	$589,858

INVESTMENT_IN_UNCONSOLIDATED_S2

INVESTMENT IN UNCONSOLIDATED SUBSIDIARY (Details) (USD $)	12 Months Ended
INVESTMENT IN UNCONSOLIDATED SUBSIDIARY (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement of operations [Abstract]	'	'
Gains losses on equity method investments	$0	$0
Minimum [Member]	'	'
Schedule Of Equity Method Investments [Line Items]	'	'
Percentage of noncontrolling interest (in hundredths)	20.00%	'
Maximum [Member]	'	'
Schedule Of Equity Method Investments [Line Items]	'	'
Percentage of noncontrolling interest (in hundredths)	50.00%	'
Altrazeal Trading Ltd. [Member]	'	'
Schedule Of Equity Method Investments [Line Items]	'	'
Non-dilutable ownership interest (in hundredths)	'	25.00%
Unrecorded profit (loss)	'	82,740
Balance sheet [Abstract]	'	'
Total assets	'	415,248
Total liabilities	'	205,991
Total stockholders' equity	'	209,257
Statement of operations [Abstract]	'	'
Revenues	'	131,869
Net (loss)	'	-330,961
OraDisc [Member]	'	'
Schedule Of Equity Method Investments [Line Items]	'	'
Non-dilutable ownership interest (in hundredths)	'	25.00%
Statement of operations [Abstract]	'	'
Gains losses on equity method investments	$0	'

ACCRUED_LIABILITIES_Details

ACCRUED LIABILITIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accrued liabilities [Abstract]	'	'
Accrued taxes - payroll	$106,299	$106,299
Accrued compensation/benefits	148,683	213,005
Accrued insurance payable	60,113	52,629
Product rebates/returns	32	81
Other	836	951
Total accrued liabilities	$315,963	$372,965

CONVERTIBLE_DEBT_Details

CONVERTIBLE DEBT (Details) (USD $)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2012

Dec. 31, 2011

Jul. 31, 2011

Jun. 30, 2011

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Jun. 27, 2012

Dec. 31, 2013

Jun. 27, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Warrant - June 2011 Debt Offering [Member]

Warrant - July 2011 Debt Offering [Member]

Warrant - June 2012 Debt Offering [Member]

Common Stock [Member]

June 2011 Note [Member]

July 2011 Note [Member]

June 2012 Note [Member]

Secured convertible note [Member]

Warrant

June 2011 Note [Member]

July 2011 Note [Member]

June 2012 Note [Member]

Maximum [Member]

PromissoryNote

Tranche

June 2011 Note [Member]

PromissoryNote

Debt Instrument [Line Items]

Purchase price paid in cash

$500,000

Purchase price paid in the form of promissory notes

1,500,000

Number of promissory notes issued under purchase agreement

Principal amount of promissory notes

250,000

Original issue discount reflected in purchase price

200,000

Attorney's fees reflected in purchase price

10,000

Amount of monthly installment

83,333

Number of calendar days after the date of registration to commence monthly installment

'30 days

Monthly installment payment terms

'If the monthly installment is paid in common stock, such shares being issued will be based on a price that is 80% of the average of the three lowest volume weighted average prices of the shares of common stock during the preceding twenty trading days. The percentage declines to 70% if the average of the three lowest volume weighted average prices of the shares of common stock during the preceding twenty trading days is less than $0.05.

Percentage of weighted average prices of shares of common stock (in hundredths)

80.00%

Declined percentage of weighted average prices of shares of common stock (in hundredths)

70.00%

Preceding number of trading days to calculate weighted average common stock price

'20 days

Weighted average price of shares of common stock, Maximum (in dollars per share)

$0.05

Amount convertible under initial tranche

710,000

Number of subsequent tranches

Amount of each subsequent tranche plus interest

250,000

Percentage of outstanding principal balance prepaid in cash (in hundredths)

120.00%

Entry amount of judgment not stayed

100,000

Period with in which judgment not stayed

'30 days

Increased interest rate in the event of default (in hundredths)

18.00%

Annual principal payment

14,653

14,001

11,542

Conversion number of equity instruments (in shares)

116,667

115,741

Amortization of debt discount on convertible notes

178,548

97,901

Stock price trigger (in dollars per share)

$2.16

Information relating to convertible notes payable [Abstract]

Initial Principal Amount

2,475,000

2,210,000

140,000

125,000

Interest Rate (in hundredths)

8.00%

10.00%

12.00%

Maturity Date

27-Mar-15

13-Jun-14

28-Jul-14

Conversion Price (in dollars per share)

$0.70

$0.35

$1.08

$1.20

$0.35

[1],[2]

$1.20

[1],[2]

$1.08

[1],[2]

$1.80

Principal Balance

1,358,638

140,000

125,000

1,093,638

Unamortized Debt Discount

211,581

1,780

4,262

205,539

Carrying Value

1,147,057

138,220

120,738

888,099

Interest cost recognized

157,027

117,711

Interest payable

553

2,080

492

1,643

Deferred Interest Payable

12,501

Reduction of notes payable

317,000

Shares issued (in shares)

725,274

435,502

Current maturity of long-term debt

152,000

Notice prior to the relevant payment date

'15 days

Number of warrant shares of common stock (in shares)

4,665,451

[3]

2,041,165

612,594

116,667

35,000

Future Minimum payments due, convertible notes [Abstract]

2014

1,358,638

140,000

125,000

1,093,638

2015

2016

2017

2018

Total

$1,358,638

$140,000

$125,000

$1,093,638

Class of Warrant or Right [Line Items]

Number of warrants

Number of securities called by warrants (in shares)

4,445,714

1,571,428

35,000

34,722

3,142,857

Exercise price of warrants (in dollars per share)

$0.35

$1.08

$0.35

Number of warrants that vest upon payment of notes (in shares)

Number of securities vested (in shares)

392,857

785,714

392,857

Shares issued on exercise of warrants (in shares)

725,274

435,502

Warrants exercised (in shares)

1,571,428

Minimum period during which registration statement is to be declared effective after filing with the SEC

'90 days

Maximum period during which registration statement is to be declared effective after filing with SEC

'180 days

[1]

[2]

The outstanding principal balance of the June 2012 Note may be converted, at the option of Inter-Mountain, into shares of common stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations.

[3]

As part of the June 2012 Note, Inter-Mountain received a total of seven warrants to purchase, if they all vest, an aggregate of 3,142,857 shares of common stock, which number of shares could increase based upon the terms and conditions of the warrants. The warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017. Warrants for 785,714, 392,857, 392,857, and 392,857 shares of common stock vested on June 27, 2012, December 31, 2012, February 26, 2013, and July 15, 2013, respectively, and three warrants for 1,571,428 shares of common stock have been exercised. For the purposes of this Table, only such net vested shares of common stock from the fourth warrant (392,857 shares) have been included, based upon an exercise price of $0.35 per share of common stock. On January 22, 2014, we elected to offset and deduct the three remaining Investor Notes from the principle amount due to Inter-Mountain under the June 2012 Note and as a result of the offset and deduction the three remaining warrants terminated.

EQUITY_TRANSACTIONS_Details

EQUITY TRANSACTIONS (Details) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2012

Jan. 31, 2014

Dec. 31, 2013

Nov. 14, 2013

Oct. 24, 2013

Sep. 06, 2013

Jul. 15, 2013

7-May-13

Mar. 14, 2013

Jan. 03, 2013

Apr. 30, 2014

Mar. 31, 2014

Mar. 14, 2014

Feb. 28, 2014

Jan. 31, 2014

Jan. 06, 2014

Jan. 03, 2014

Dec. 31, 2013

Mar. 14, 2013

Dec. 31, 2013

Dec. 21, 2012

Apr. 30, 2014

Mar. 31, 2014

Feb. 28, 2014

Jan. 31, 2014

Dec. 31, 2013

Apr. 30, 2014

Mar. 31, 2014

Jan. 31, 2014

Subsequent Event [Member]

SPA [Member]

Common Stock [Member]

Director

Subsequent Event [Member]

March SPA [Member]

SPA [Member]

Sacks [Member]

TPT [Member]

Four-month anniversary [Member]

Eight-month anniversary [Member]

One-year anniversary [Member]

Four-month anniversary [Member]

Eight-month anniversary [Member]

One-year anniversary [Member]

Subsequent Event [Member]

Common Stock Transactions [Abstract]

Equity investment

$440,000

$2,000,000

Common Stock, par value (in dollars per share)

$0.35

$0.00

Maximum amount of common stock purchased under Common Stock Purchase Agreement

88,000

110,000

132,000

110,000

400,000

500,000

600,000

500,000

Share price (in dollars per share)

$0.60

Issuance of shares of common stock under securities purchase agreement (in shares)

1,100,000

5,000,000

Number of securities called by warrants (in shares)

4,445,714

1,571,428

3,000,000

660,000

3,000,000

Proceeds from offering

$132,000

$300,000

$110,000

$500,000

$88,000

$400,000

$450,000

$110,000

$450,000

$500,000

Shares purchased under stock purchased agreement (in shares)

330,000

750,000

275,000

1,250,000

220,000

1,000,000

275,000

1,250,000

Number of maximum directors that could be appointed

Shares issued on exercise of warrants (in shares)

725,274

750,000

Issuance Of Shares Of Common Stock under assignment agreement

250,000

750,000

2,000,000

500,000

1,000,000

Number of days within which request is declared effective

'60 days

Number of days for which statement is effective

'80 days

Number of additional days for which filing of statement can be done

'60 days

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jul. 15, 2013

Feb. 26, 2013

Jun. 27, 2012

Jan. 22, 2014

Dec. 31, 2013

Kerry P. Gray [Member]

Terrace K. Wallberg [Member]

Inter-Mountain [Member]

Warrant - June 2012 Debt Offering [Member]

January 3, 2014 [Member]

July 23, 2014 [Member]

May 15, 2015 [Member]

June 13, 2016 [Member]

July 16, 2016 [Member]

July 28, 2016 [Member]

June 27, 2017 [Member]

March 14, 2018 [Member]

Series A Preferred Stock [Member]

Private Placement [Member]

Inter-Mountain [Member]

Common Stock [Abstract]

Common Stock, shares issued (in shares)

18,871,420

10,074,448

Common Stock, shares outstanding (in shares)

18,871,420

10,074,448

Common stock issued during period (in shares)

8,796,972

Number of shares of common stock issued for IPMD pursuant (in shares)

3,750,000

Stock issued in lieu of offering agreement (in shares)

825,000

Number shares of common stock issued for installment payments (in shares)

3,072,648

Shares issued on exercise of warrants (in shares)

725,274

Common stock issued for consulting services (in shares)

363,750

Common stock issued in lieu of wages (in shares)

60,000

Number of shares of common stock issued for vesting of restricted stock awards (in shares)

300

Preferred Stock [Abstract]

Preferred stock, shares issued (in shares)

Preferred stock, shares outstanding (in shares)

Preference shares redeemed by offset of promissory note receivable (in shares)

-65

Promissorry note offset on preference share redemption

($969,000)

Term of note

'7 years 6 months

Warrants and number of shares of common stock subject to exercise [Roll Forward]

Balance (in shares)

2,041,165

612,594

392,857

785,714

3,000,000

69,050

357,155

35,000

116,667

34,722

392,857

660,000

Warrants issued (in shares)

4,445,714

1,428,571

Warrants exercised (in shares)

-1,571,428

[1]

Warrants cancelled (in shares)

-250,000

Balance (in shares)

4,665,451

[1]

2,041,165

392,857

785,714

3,000,000

69,050

357,155

35,000

116,667

34,722

392,857

660,000

Warrants, weighted-average exercise price [Abstract]

Balance (in dollars per share)

$0.98

$2.45

Warrants issued (in dollars per share)

$0.56

$0.35

Warrants exercised (in dollars per share)

$0.35

[1]

Warrants cancelled (in dollars per share)

$0.35

Balance (in dollars per share)

$0.82

[1]

$0.98

Warrant shares subject to expiration [Abstract]

Number of warrant shares of common stock subject to expiration (in shares)

4,665,451

[1]

2,041,165

392,857

785,714

3,000,000

69,050

357,155

35,000

116,667

34,722

392,857

660,000

Number of warrants to purchase common stock (in shares)

Aggregate shares of common stock issued upon exercise of warrants (in shares)

4,445,714

1,571,428

600,000

60,000

785,714

3,142,857

3,000,000

Number of warrants exercised (in shares)

Aggregate shares of common stock issued upon exercise of warrants (in shares)

4,445,714

1,571,428

600,000

60,000

785,714

3,142,857

3,000,000

Number of warrants terminated (in shares)

Common stock vested upon initial warrant (in shares)

4,665,451

[1]

2,041,165

392,857

785,714

3,000,000

69,050

357,155

35,000

116,667

34,722

392,857

660,000

Exercise price of warrants (in dollars per share)

$0.35

$0.60

$0.35

$0.60

[1]

EARNINGS_PER_SHARE_Details

EARNINGS PER SHARE (Details) (USD $)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2012

Dec. 31, 2011

Jul. 31, 2011

Jun. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Jul. 15, 2013

Feb. 26, 2013

Jun. 27, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Warrants to purchase common stock [Member]

Stock options to purchase common stock [Member]

Unvested restricted common stock [Member]

Common stock issuable upon the assumed conversion of our convertible note payable from June 2012 [Member]

Common stock issuable upon the assumed conversion of our convertible notes payable from June 2011 and July 2011 [Member]

Common stock issuable upon the assumed conversion of our Series A preferred stock [Member]

Warrant

Private Placement [Member]

InvestorNote

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from calculating basic and diluted net loss per common share (in shares)

9,058,353

9,189,119

4,665,451

[1]

2,041,165

[1]

1,014,907

158,409

300

3,124,680

[2]

5,617,974

[2]

253,315

[3]

368,637

[3]

[4],[5]

1,002,634

[4],[5]

Number of warrants to purchase common stock (in shares)

Aggregate shares of common stock issued upon exercise of warrants (in shares)

4,445,714

1,571,428

3,142,857

Common stock vested upon initial warrant (in shares)

4,665,451

[1]

2,041,165

612,594

392,857

785,714

392,857

Exercise price of warrants (in dollars per share)

$0.35

Average number of trading days prior to the payment of note taken to calculate the conversion price

'5 days

Conversion price (in dollars per share)

$0.70

$0.35

$1.08

$1.20

Number of months from date of issuance of Series A preferred stock taken for conversion of accrued dividends

'6 months

Warrants exercised (in shares)

-1,571,428

[1]

1,571,428

Number of warrants exercised

Investor notes elected to offset and deduct

Number of warrants terminated

Preference shares redeemed by offset of promissory note receivable (in shares)

Promissorry note offset on preference share redemption

($969,000)

$969,000

Term of note

'7 years 6 months

[1]

[2]

The outstanding principal balance and the accrued and unpaid interest of the June 2012 Note may be converted, at the option of Inter-Mountain, into shares of common stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations. For the purposes of this Table, we have assumed a conversion price of $0.35 per share and no ownership limitations.

[3]

The outstanding principal balance of the June 2011 Note and the July 2011 Note may be converted, at the option of Mr. Gray, into shares of common stock at a fixed conversion price of $1.20 per share and $1.08 per share, respectively. The accrued and unpaid interest for each convertible note payable may be converted, at the option of Mr. Gray, into shares of common stock at a conversion price based upon the average of the five trading days prior to the payment date, which for the purposes of this Table we have assumed to be December 31, 2013.

[4]

On August 15, 2013, we provided notice to Ironridge for the redemption of all of our Series A Shares held by Ironridge, a total of 65 Series A Shares. An affiliate of Ironridge, the issuer of promissory notes held by us, due 7.5 years from the issue date, in the principal amount of $969,000, agreed to accept the cancellation of the promissory notes held by us as full and final payment for the redemption amounts of the Series A Shares.

[5]

The outstanding Series A preferred stock and the accrued and unpaid dividends thereon are convertible into shares of the Companybs common stock at the Companybs option at any time after six-months from the date of issuance of the Series A preferred stock. The conversion price for the holder is fixed at $0.70 per share with no adjustment mechanisms, resets, ratchets, or anti-dilution covenants other than the customary adjustments for stock splits. For the purposes of this Table, we have assumed a conversion price of $0.70 per share.

SHARE_BASED_COMPENSATION_Detai

SHARE BASED COMPENSATION (Details) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jun. 13, 2013

Jun. 14, 2012

Jun. 15, 2010

Dec. 17, 2009

8-May-07

Dec. 31, 2013

Incentive Stock Options [Member]

Nonstatutory Stock Options [Member]

Stock Options [Member]

Restricted Stock [Member]

2006 Equity Incentive Plan [Member]

Minimum [Member]

Maximum [Member]

Stock Options [Member]

Restricted Stock [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Weighted average assumptions to estimate the fair value of share-based awards [Abstract]

Expected volatility (in hundredths)

103.55%

[1]

0.00%

[1],[2]

103.55%

[1]

0.00%

[1],[2]

Risk-fee interest rate % (in hundredths)

0.81%

[3]

0.00%

[2],[3]

0.81%

[3]

0.00%

[2],[3]

Expected term (in years)

'5 years

'0 years

[2]

'5 years

'0 years

[2]

Dividend yield (in hundredths)

0.00%

[4]

0.00%

[2],[4]

0.00%

[4]

0.00%

[2],[4]

Options Granted [Abstract]

Quantity (in shares)

232,500

[2]

735,000

[2]

967,500

Weighted average fair value per share (in dollars per share)

$0.24

[2]

$0.24

[2]

Fair value

$56,112

[2]

$177,388

[2]

Options, Outstanding [Roll Forward]

Outstanding, beginning of period (in shares)

158,409

287,745

Granted (in shares)

232,500

[2]

735,000

[2]

967,500

Forfeited/cancelled (in shares)

-111,002

-129,336

Exercised (in shares)

Outstanding, end of period (in shares)

1,014,907

158,409

Outstanding, Weighted Average Exercise Price [Roll Forward]

Outstanding, beginning of period (in dollars per share)

$12.32

$16.89

Granted (in dollars per share)

$0.33

Forfeited/cancelled (in dollars per share)

$1.03

$22.49

Exercised (in dollars per share)

Outstanding, end of period (in dollars per share)

$2.12

$12.32

Nonvested restricted stock awards, Number of Shares [Roll Forward]

Outstanding, beginning of period (in shares)

300

1,096

Granted (in shares)

Forfeited/cancelled (in shares)

-97

Exercised/issued (in shares)

-300

-699

Outstanding, end of period (in shares)

300

Nonvested restricted stock awards, Weighted Average Grant Date Fair Value [Roll Forward]

Outstanding, beginning of period (in dollars per share)

$34.59

$41.47

Granted (in dollars per share)

Forfeited/cancelled (in dollars per share)

$34.59

Exercised/issued (in dollars per share)

$34.59

$45.39

Outstanding, end of period (in dollars per share)

$34.59

Additional disclosures [Abstract]

Vesting period

'6 months

'5 years

'1 year

'4 years

'6 months

'5 years

Number of shares authorized (in shares)

133,333

Number of additional shares authorized (in shares)

600,000

400,000

200,000

266,667

1,800,000

Contractual term

'10 years

Number of options granted to date (in shares)

1,376,167

Number of restricted shares granted to date (in shares)

68,616

Number of shares available for grant (in shares)

715,647

Nonvested Awards, unearned share-based compensation [Abstract]

Unearned share-based compensation expense

$152,443

Unearned share-based compensation, recognition period

'27 months

[1]

Expected volatility assumption was based upon a combination of historical stock price volatility measured on a daily basis and an estimate of expected future stock price volatility.

[2]

The Company did not award any incentive stock options for the year ended December 31, 2012.

[3]

Risk-free interest rate assumption is based upon U.S. Treasury bond interest rates appropriate for the term of the stock options.

[4]

The Company does not currently intend to pay cash dividends, thus has assumed a 0% dividend yield.

SHARE_BASED_COMPENSATION_Alloc

SHARE BASED COMPENSATION, Allocated Compensation expense (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Stock Options [Member]	'	'
Allocation of Recognized Period Costs [Line Items]	'	'
Share-based compensation expense	$80,939	$37,897
Stock Options [Member] \| Research and Development [Member]	'	'
Allocation of Recognized Period Costs [Line Items]	'	'
Share-based compensation expense	16,863	6,280
Stock Options [Member] \| Selling, General and Administrative [Member]	'	'
Allocation of Recognized Period Costs [Line Items]	'	'
Share-based compensation expense	64,076	31,617
Restricted Stock [Member]	'	'
Allocation of Recognized Period Costs [Line Items]	'	'
Share-based compensation expense	991	8,297
Restricted Stock [Member] \| Research and Development [Member]	'	'
Allocation of Recognized Period Costs [Line Items]	'	'
Share-based compensation expense	444	3,762
Restricted Stock [Member] \| Selling, General and Administrative [Member]	'	'
Allocation of Recognized Period Costs [Line Items]	'	'
Share-based compensation expense	$547	$4,535

SHARE_BASED_COMPENSATION_Stock

SHARE BASED COMPENSATION, Stock options grant outstanding and excercisable (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Stock option grants outstanding and exercisable [Line Items]	'
Stock Options Outstanding (in shares)	1,014,907
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$2.12
Options Outstanding, Weighted Average Remaining Contractual Life in Years	'8 years 7 months 6 days
Stock Options Exercisable (in shares)	313,241
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$6.10
Exercise Price Range 1 [Member]	'
Stock option grants outstanding and exercisable [Line Items]	'
Stock Options Outstanding (in shares)	892,500
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$0.33
Options Outstanding, Weighted Average Remaining Contractual Life in Years	'9 years 2 months 12 days
Stock Options Exercisable (in shares)	197,500
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$0.33
Exercise Price Range 2 [Member]	'
Stock option grants outstanding and exercisable [Line Items]	'
Stock Options Outstanding (in shares)	53,334
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$2.38
Options Outstanding, Weighted Average Remaining Contractual Life in Years	'4 years 6 months
Stock Options Exercisable (in shares)	46,668
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$2.36
Exercise Price Range 3 [Member]	'
Stock option grants outstanding and exercisable [Line Items]	'
Stock Options Outstanding (in shares)	30,002
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$14.40
Options Outstanding, Weighted Average Remaining Contractual Life in Years	'3 years 3 months 18 days
Stock Options Exercisable (in shares)	30,002
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$14.40
Exercise Price Range 4 [Member]	'
Stock option grants outstanding and exercisable [Line Items]	'
Stock Options Outstanding (in shares)	39,071
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$33.35
Options Outstanding, Weighted Average Remaining Contractual Life in Years	'3 years 9 months 18 days
Stock Options Exercisable (in shares)	39,071
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$33.35

EMPLOYMENT_BENEFIT_PLAN_Detail

EMPLOYMENT BENEFIT PLAN (Details) (USD $)	12 Months Ended
EMPLOYMENT BENEFIT PLAN (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
EMPLOYMENT BENEFIT PLAN [Abstract]	'	'
Contributions made to 401(k) plan	$20,917	$25,085

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Assets [Abstract]	'	'
Notes receivable and accrued interest	$777,710	$1,302,220
Convertible note - June 2011 [Member]	'	'
Liabilities [Abstract]	'	'
Convertible note payable	138,220	134,154
Convertible note - July 2011 [Member]	'	'
Liabilities [Abstract]	'	'
Convertible note payable	120,738	113,084
Convertible note - June 2012 [Member]	'	'
Liabilities [Abstract]	'	'
Convertible note payable	$888,099	$1,593,924

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	12 Months Ended
INCOME TAXES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Expiration of Operating Loss Carryforwards and Research Credit Carryforwards [Line Items]	'	'
Consolidated operating loss carryforwards	$49,550,149	'
Research activities carryforwards	511,949	'
Period of cumulative changes in ownership considered for limit on operating loss and tax credit carryforwards	'3 years	'
Minimum percentage of cumulative changes in ownership considered for limit on operating loss and tax credit carryforwards (in hundredths)	50.00%	'
Deferred tax assets [Abstract]	'	'
Net operating loss carryforwards	17,657,746	16,549,134
Intangible assets	247,248	305,552
Other	512,286	502,732
Total gross deferred tax assets	18,417,280	17,357,418
Deferred tax liabilities [Abstract]	'	'
Property and equipment	72,347	77,839
Total gross deferred tax liabilities	72,347	77,839
Net total of deferred assets and liabilities	18,344,933	17,279,579
Valuation allowance	-18,344,933	-17,279,579
Net deferred tax assets	0	0
Increase in valuation allowance	1,065,354	1,225,683
Reconciliation of expected statutory federal income tax rate to actual income tax rate [Abstract]	'	'
Expected income tax (benefit) at federal statutory tax rate -35%	-1,137,320	-1,309,975
Permanent differences	21,754	16,500
Research tax credits	-15,882	-8,690
Amortization of deferred start up costs	0	0
Valuation allowance	1,131,448	1,302,165
Income tax expense	0	0
Federal statutory tax rate (in hundredths)	35.00%	'
Liability for unrecognized tax benefits	0	0
2021 [Member]	'	'
Expiration of Operating Loss Carryforwards and Research Credit Carryforwards [Line Items]	'	'
Consolidated operating loss carryforwards	34,248	'
Research activities carryforwards	0	'
2023 [Member]	'	'
Expiration of Operating Loss Carryforwards and Research Credit Carryforwards [Line Items]	'	'
Consolidated operating loss carryforwards	95,666	'
Research activities carryforwards	0	'
2024 [Member]	'	'
Expiration of Operating Loss Carryforwards and Research Credit Carryforwards [Line Items]	'	'
Consolidated operating loss carryforwards	910,800	'
Research activities carryforwards	13,584	'
2025 [Member]	'	'
Expiration of Operating Loss Carryforwards and Research Credit Carryforwards [Line Items]	'	'
Consolidated operating loss carryforwards	1,687,528	'
Research activities carryforwards	21,563	'
2026 [Member]	'	'
Expiration of Operating Loss Carryforwards and Research Credit Carryforwards [Line Items]	'	'
Consolidated operating loss carryforwards	11,950,281	'
Research activities carryforwards	60,797	'
2027 [Member]	'	'
Expiration of Operating Loss Carryforwards and Research Credit Carryforwards [Line Items]	'	'
Consolidated operating loss carryforwards	3,431,365	'
Research activities carryforwards	85,052	'
2028 [Member]	'	'
Expiration of Operating Loss Carryforwards and Research Credit Carryforwards [Line Items]	'	'
Consolidated operating loss carryforwards	8,824,940	'
Research activities carryforwards	139,753	'
2029 [Member]	'	'
Expiration of Operating Loss Carryforwards and Research Credit Carryforwards [Line Items]	'	'
Consolidated operating loss carryforwards	6,889,761	'
Research activities carryforwards	81,940	'
2030 [Member]	'	'
Expiration of Operating Loss Carryforwards and Research Credit Carryforwards [Line Items]	'	'
Consolidated operating loss carryforwards	5,113,583	'
Research activities carryforwards	41,096	'
2031 [Member]	'	'
Expiration of Operating Loss Carryforwards and Research Credit Carryforwards [Line Items]	'	'
Consolidated operating loss carryforwards	3,728,626	'
Research activities carryforwards	43,592	'
2032 [Member]	'	'
Expiration of Operating Loss Carryforwards and Research Credit Carryforwards [Line Items]	'	'
Consolidated operating loss carryforwards	3,695,792	'
Research activities carryforwards	8,690	'
2033 [Member]	'	'
Expiration of Operating Loss Carryforwards and Research Credit Carryforwards [Line Items]	'	'
Consolidated operating loss carryforwards	3,187,559	'
Research activities carryforwards	$15,882	'

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)

3 Months Ended

12 Months Ended

21 Months Ended

60 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Mar. 07, 2008

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Mar. 09, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2011

Dec. 31, 2013

Access Pharmaceuticals [Member]

ProStrakan Ltd [Member]

Kerry P. Gray [Member]

Terrance K. Wallberg [Member]

Key Executives [Member]

Chairman, CEO and President [Member]

Accounts Receivable [Member]

Sales Revenue, Net [Member]

Office and Laboratory Space [Member]

Office Equipment [Member]

Annual Sales, Certain Products [Member]

Annual Sales, Any One Certain Product [Member]

Cumulative Sales, Certain Products [Member]

Maximum [Member]

Customer Concentration Risk [Member]

March 31, 2014 [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Operating Leased Assets [Line Items]

Minimum monthly lease obligation

$9,193

$9,776

$9,330

$9,379

$744

Future minimum lease payments [Abstract]

2014

120,917

2015

28,881

2016

2017

2018

Total

149,798

Rent expense for operating lease

116,488

130,065

Concentration Risk [Line Items]

Revenues

129,060

110,580

28,884

102,044

165,456

88,922

56,211

60,005

370,568

370,594

281,000

117,000

Accounts receivable, net

185,078

111,898

185,078

111,898

174,000

101,000

Concentration risk percentage (in hundredths)

67.00%

59.00%

97.00%

77.00%

76.00%

32.00%

Separation Agreements [Line Items]

Total separation benefit payments

400,000

Period for separation benefit payments

'48 months

'12 months

Monthly separation benefits payments

12,500

Forfeited stock options due to separation (in shares)

20,000

Period for separation health coverage

'24 months

Deferred compensation

221,500

Separation agreement

11,500

Stipend for being the Chairman of the Executive Committee

210,000

Repaid deferred compensation

-312,500

Required funding

-300,000

Summary of compensation earned, compensation paid in cash, and compensation temporarily deferred [Abstract]

Deferred Compensation Liability

-146,739

272,156

197,838

-91,000

[1]

220,673

[1]

140,313

[1]

-35,769

24,230

36,539

-20,000

27,253

20,986

Compensation - Deferred

323,225

469,994

323,225

469,994

269,986

[1]

25,000

28,239

Compensation Accounts Payable

207,500

310,000

207,500

310,000

Compensation Accrued Liabilities

115,725

159,994

115,725

159,994

Milestone payments [Line Items]

Future milestone obligations

4,750,000

1,400,000

Milestone for payment

$20,000,000

$40,000,000

$20,000,000

$50,000,000

$100,000,000

Royalty percentage (in hundredths)

30.00%

[1]

During 2013, Mr. Gray temporarily deferred compensation of $221,500 which consisted of $11,500 earned pursuant to a Separation Agreement and $210,000 for his duties as Chairman of the Executive Committee of the Companybs Board of Directors. During 2013, Mr. Gray was also repaid $312,500 of temporarily deferred compensation, of which $300,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.

LEGAL_PROCEEDINGS_Details

LEGAL PROCEEDINGS (Details)	12 Months Ended
LEGAL PROCEEDINGS (Details)	Dec. 31, 2013
LEGAL PROCEEDINGS [Abstract]	'
Percentage of voting securities (in hundredths)	5.00%

SELECTED_QUARTERLY_FINANCIAL_D2

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Selected Quarterly Financial Information [Abstract]	'	'	'	'	'	'	'	'	'	'
Revenues	$129,060	$110,580	$28,884	$102,044	$165,456	$88,922	$56,211	$60,005	$370,568	$370,594
Costs and expenses	880,888	743,033	744,932	649,413	1,034,259	837,149	884,289	879,717	3,018,266	3,635,414
Operating (loss)	-751,828	-632,453	-716,048	-547,369	-868,803	-748,227	-828,078	-819,712	-2,647,698	-3,264,820
Other income (expense)	-106,442	-110,816	-106,737	-109,221	-109,266	-103,498	-30,068	-23,697	'	'
Net (loss)	-858,270	-743,269	-822,785	-656,590	-978,069	-851,725	-858,146	-843,409	-3,080,914	-3,531,349
Less preferred stock dividends	0	-6,061	-12,154	-12,021	-12,288	-12,288	-12,154	-10,726	'	'
Net (loss) allocable to common stockholders	($858,270)	($749,330)	($834,939)	($668,611)	($990,357)	($864,013)	($870,300)	($854,135)	($3,111,150)	($3,578,805)
Basic and diluted net (loss) per common share (in dollars per share)	($0.04)	($0.05)	($0.06)	($0.06)	($0.10)	($0.10)	($0.11)	($0.11)	($0.21)	($0.42)

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

2 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2014

Apr. 30, 2014

Mar. 31, 2014

Feb. 28, 2014

Jan. 31, 2014

Jan. 03, 2014

Apr. 30, 2014

Mar. 31, 2014

Feb. 28, 2014

Jan. 31, 2014

Apr. 30, 2014

Mar. 31, 2014

Jan. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Jan. 22, 2014

Subsequent Event [Member]

Common Stock [Member]

Sacks [Member]

TPT [Member]

Sacks Tranche One [Member]

June 2012 Note [Member]

Secured convertible note [Member]

Subsequent Event [Member]

Common Stock [Member]

June 2012 Note [Member]

Subsequent Event [Member]

Common Stock Transactions [Abstract]

Percentage of prepayment premium not incurred as per notice

120.00%

Outstanding amount of note

$1,358,638

$1,093,638

$317,029

Final payment

152,426

Number of securities called by warrants (in shares)

4,445,714

1,571,428

3,000,000

Proceeds from offering

$450,000

Shares issued (in shares)

725,274

750,000

435,502

Issuance of shares of common stock under assignment agreement (in shares)

250,000

750,000

2,000,000

500,000

1,000,000

750,000

Number of days within which request is declared effective

'60 days

Number of days for which statement is effective

'80 days

Number of additional days for which filing of statement can be done

'60 days